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High-performance affinity chromatography (HPAC) is a type of liquid 
chromatography in which solutes are separated based on their binding to a stationary 
phase that is a biologically-related agent. Sulfonylurea drugs have significant binding to 
proteins in blood, with most of this binding is believed to occur with human serum 
albumin (HSA).  HSA is known to be modified as a result of the high serum levels of 
glucose that is present during diabetes, which may also alter the function of HSA as a 
binding agent for many drugs in circulation. Some modifications of HSA that can occur 
during diabetes involves early stage glycation and advanced glycation. Drugs that may be 
affected by these changes include various sulfonylurea drugs, as are commonly used to 
treat type II diabetes.  This thesis describes the development of tools and techniques 
based on HPAC to examine the effects of glycation on the binding of HSA. A major 
portion of this research describes the use of HPAC to examine the effect of early stage 
glycation on the binding of two first-generation sulfonylurea drugs. Frontal analysis and 
zonal elution studies were used to provide information on association equilibrium 
constants and the number of binding sites for these interactions. Significant levels of both 
increases and decreases in affinity were observed for these drugs at the levels of glycation 
that were examined. A second portion of this research describes the utilization of HPAC 
to investigate the effect of advance glycation on the binding of two first-generation 
sulfonylurea drugs and one second-generation sulfonylurea drug. Two major advanced 
glycation end-products (AGEs) of HSA, glyoxal- and methylglyoxal-modified HSA, 
were studied in this work. Immunoextraction and zonal elution were used to estimate the 
global affinity of these drugs with normal or in vitro modified HSA, while competition 
studies based on zonal elution were used to measure the binding strengths of these drugs 
at specific sites on these preparations of HSA.  
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CHAPTER 1 
OVERVIEW OF THESIS  
1.1 Overview of thesis 
High-performance affinity chromatography (HPAC) is a type of liquid 
chromatography in which solutes are separated based on their binding to a stationary 
phase that is a biologically-related agent. Sulfonylurea drugs have significant binding to 
proteins in blood, with most of this binding is believed to occur with human serum 
albumin (HSA).  HSA is known to be modified as a result of the high serum levels of 
glucose that is present during diabetes, which may also alter the function of HSA as a 
binding agent for many drugs in circulation. Some modifications of HSA that can occur 
during diabetes involves early stage glycation and advanced glycation. Drugs that may be 
affected by these changes include various sulfonylurea drugs, as are commonly used to 
treat type II diabetes.  This thesis describes the development of tools and techniques 
based on HPAC to examine the effects of glycation on the binding of HSA.  
The Chapter 2 provides a general introduction to HPAC and explained how 
HPAC can be used to examine interactions between drugs and proteins.  The method of 
frontal analysis is introduced and described as a method for determining the global 
affinity binding of a drug with a protein. Zonal elution will also be introduced as a 
method that can be utilized to investigate the association equilibrium constants at specific 
sites on a protein with drugs.   
          Chapters 3 and 4 describe the use of HPAC to profile the binding of two first-
generation sulfonylurea drugs (i.e., chlorpropamide and tolazamide) to normal HSA and 
samples of HSA with levels of glycation corresponding to controlled or advanced 
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diabetes. Frontal analysis and zonal elution competition studies will be applied and 
provided information on binding of drug with normal and glycated HSA. The results 
obtained from these experiments will indicate how much changes in affinity of binding 
between these sulfonylureas and HSA due to early stage glycation. 
Chapter 5 and 6 describe the utilization of HPAC to profile the binding of two 
first-generation sulfonylurea drugs (chlorpropamide and tolazamide) and second-
generation sulfonylurea drugs (gliclazide) to samples of HSA with levels of advanced 
stage glycation (i.e., glyoxal and methylglyoxal modification) corresponding to healthy 
individuals or those with controlled diabetes. Immunoextraction zonal elution and 
competition studies will be used to examine the effects of advanced stage glycation on 
the binding of HSA. The results obtained from these experiments will indicate how much 
changes in affinity of binding between these sulfonylureas and HSA due to advanced 
stage glycation. 
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CHAPTER 2 
HIGH-PERFORMANCE AFFINITY CHROMATOGRAPHY: APPLICATIONS 
IN DRUG-PROTEIN BINDING STUDIES  
Portions of this material have previously appeared in the following publication and are 
reproduced with permission: P. Tao, S. Poddar, Z. Sun, D.S. Hage, J. Chen, Analysis of 
solute-protein interactions and solute-solute competition by zonal elution affinity 
chromatography, Methods 146 (2018) 3–11.  
2.1 Introduction    
High performance affinity chromatography (HPAC) is a chromatographic 
technique that uses an immobilized binding agent (e.g., a protein) as the stationary phase 
[1-3].  In previous work, HPAC has been used to isolate and analyze various specific 
targets; due to its versatility, this approach can also be applied to studying the interactions 
between biological molecules in methods that provide fast analysis times and have good 
precisions. In this thesis, HPAC’s ability to determine binding regions, equilibrium 
constants, and the amounts of binding sites for drug-protein interactions will be utilized 
[1-8]. 
Human serum albumin (HSA) is most abundant serum protein in humans. HSA 
makes up more than 50% of an individual’s plasma proteins, with a normal concentration 
between 30–50 mg/ml. This plasma protein is a single chain globular protein with a 
molecular weight of 66.5 kDa [9]. It contains 585 amino acids, including 35 cysteines, 1 
tryptophan, 59 lysines, and 17 disulfide chains [9-15]. HSA has two major binding sites 
for drugs: Sudlow sites I and II [9].  Sudlow site I is located in subdomain IIA of HSA 
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and is known to bind many types of hydrophobic drugs, such as warfarin and salicylate 
[12].  Sudlow site II is located in subdomain IIIA of HSA and is known to bind to L-
tryptophan, ibuprofen, and ketoprofen, as well as many other drugs and solutes [12].  In 
previous reports it has been found that both of these binding sites can bind to many drugs 
that are used to treat type II diabetes, such as acetohexamide and tolbutamide [13-15]. 
High levels of glucose during diabetes can result in the modification of serum 
proteins, such as through the glycation of HSA.  Glycation is a non-enzymatic 
modification in which reducing sugars bind to proteins [16].  The glycation of proteins 
has been linked to many of the long-term complications of diabetes [16].   Glycation can 
lead to both early stage products (e.g., fructosamines) and advanced glycation end-
products (AGEs) such as argpyrimidine, and imidazolone [16].  In addition, it is known 
that both Sudlow sites I and II can be modified as a result of glycation and that these 
modifications can affect the binding by HSA to various anti-diabetic drugs [17-21]. 
Sulfonylurea drugs are commonly used to treat type II diabetes by oral 
administration. The core structure of sulfonylurea drugs is shown in Fig. 2-1 and is 
composed of two main groups: a phenylsulfonyl group and a urea group. The first-
generation sulfonylurea drugs chlorpropamide and tolazamide have been found to bind 
tightly with HSA; these drugs can lower elevated glucose levels in human blood by 
binding to ATP K+ channels in pancreatic beta cells and inducing closure of these 
channels [22-26].  Overall, these sulfonylurea drugs can lower high glucose levels in 
blood by closing the K+ channel in pancreatic cells and opening the Ca2+ channel, which 
can stimulate insulin secretion from the pancreas [22-26].   
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This work will use HPAC to investigate the binding of sulfonylurea drugs to 
normal HSA, glycated HSA and HSA that has been modified to contain advanced 
glycation end-products (AGEs).  The method of frontal analysis will be used to determine 
the overall equilibrium constants and the moles of binding sites for sulfonylurea drugs 
with HSA.  Zonal competition studies will also be employed to examine the interactions 
of sulfonylurea drugs with Sudlow sites I and II on HSA.  The results obtained from this 
work should provide a better understanding of the effects of glycation and AGE 
formation on HSA and of how these processes alter the binding of sulfonylurea drugs to 
HSA at different stages of diabetes.   
 
2.2 Zonal elution studies of drug-protein interactions  
Zonal elution is the most prevalent form of affinity chromatography that is used 
for the analysis of solute-protein interactions and solute-solute competition for binding 
sites on proteins [27-31].  In this method, a small amount of an analyte or solute (A) is 
injected into a chromatographic system that contains an affinity column with an 
immobilized biological ligand or binding agent (L). This injection is often made in the 
presence of a mobile phase that contains a known concentration of a competing agent or 
interacting agent (I). The time or mobile phase volume that is required to elute the solute 
from the column is then monitored and used to provide information on the interactions 
between the injected solute, the agent in the mobile phase, and/or the immobilized 
binding agent [32]. This section 2.2 will examine the theory, principles and applications 
of zonal elution affinity chromatography method in the study of solute-protein binding 
and solute-solute competition for proteins.  
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A typical HPLC system for performing a zonal elution experiment is shown in 
Figure 2-2 [32]. This particular system design includes an online detector; however, a 
fraction collector and an offline detector can also be employed, particularly when the 
experiment involves a low-performance affinity column [30,32-33]. Temperature control 
is ideally needed for this type of system to obtain optimum precision and accuracy [32]. 
Linear elution conditions are also often required, in which the amount of the injected 
solute is negligible compared to the amount of the binding agent in the column [28,32,34]. 
However, nonlinear elution conditions can be employed in some situations for zonal 
elution experiments [35-37]. There are several advantages to using zonal elution and 
affinity chromatography for the analysis of solute-protein binding and solute-solute 
competition. First, only a small amount of solute is needed per injection and the same 
preparation of an immobilized binding agent can often be used for many experiments 
[30,32]. In addition, it is possible in some situations (e.g., with chiral compounds) to 
examine the binding by more than one solute per run, as long as sufficient resolution is 
present to differentiate between the corresponding peaks for these solutes [30]. There are 
several other advantages when using this type of method as part of an HPLC system, 
including the good precision and speed of HPLC as well as the variety of detectors that 
can be used to monitor solute elution [38]. Zonal elution has several additional 
advantages when compared to frontal analysis, which is the other major form of affinity 
chromatography that is used for binding studies [32]. These advantages include the 
ability of zonal elution to work with a smaller amount of a solute than frontal analysis 
and the longer time that is often needed for frontal analysis experiments. Zonal elution 
can also be used in work with binding agents that may contain multiple sites for a solute 
7 
 
and can allow binding strengths to be measured at individual sites [39-40]. The main 
disadvantages of zonal elution are that frontal analysis tends to give more precise binding 
constants and can be used to independently determine both the number of binding sites 
that are present for a solute and the equilibrium constants for each group of sites [32]. 
Zonal elution has been employed in many reports for examining competition and 
displacement in solute-ligand systems [41]. In this type of study, an analyte or solute is 
injected into an affinity column in the presence of a mobile phase that contains a fixed 
concentration of a possible competing agent. An example of such a study was given 
earlier in Fig. 2-3 [42]. From the change in retention that is observed for the solute as the 
concentration of the competing agent is varied, it can be determined whether the two 
solutes are interacting as they bind to the same affinity ligand [32]. 
The nature of this interaction can be determined by comparing the change in the 
measured retention with the response that is expected for various models [32]. Examples 
of interactions that may be present include direct competition between the injected 
analyte and agent in the mobile phase, allosteric interactions, or the absence of any 
interactions between these two chemicals with the immobilized binding agent [41]. One 
way these interactions can be examined is by making a plot of the retention data 
according to Eq. (2-1). 
                                         
1
  kA
=
𝐾𝐼[D]
𝐾𝐴 𝐶𝐿
+
1
𝐾𝐴 𝐶𝐿
                                                  (2-1) 
In this equation, kA is the retention factor for the injected analyte; KA and KI are 
the association equilibrium constants for the analyte and the competing agent, 
respectively, at their site of competition; [I] is the concentration of the competing agent; 
and CL is the concentration of the affinity ligand in the column. A corrected retention 
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factor that is equal to the term kA − X is also sometimes used instead of kA in Eq. (2-1), 
where X represents the retention factor for the injected analyte due to binding sites in the 
column at which competing agent has no interactions [39]. 
Fig. 2-4 shows the results that are obtained for various types of interactions when 
a plot of 1/kA versus the competing agent concentration is made according to Eq. (2-1) 
[40]. In the absence of any competition between the analyte and mobile phase additive, a 
plot that is prepared in this manner shows only random variations about a horizontal line, 
as illustrated in Fig. 2-4(a) for digitoxin as the injected analyte and when 
using glimepiride as a mobile phase additive. When direct competition is present at the 
same binding site for the analyte and competing agent, a linear plot with a positive slope 
is generated, as shown in Fig.2-4(b) for L-tryptophan as the analyte and in the presence 
of mobile phases containing glimepiride. Deviations from a positive linear response, as 
demonstrated in Fig. 2-4(c) for injections of R-warfarin as the analyte and glimepiride as 
the mobile phase additive, can occur if a negative allosteric effect or multisite 
competition is present. A positive allosteric interaction results in a plot like the one 
shown in Fig. 2-4(d) for tamoxifen as the analyte tamoxifen and glimepiride as the 
mobile phase additive, in which the value 1/kA decreases with an increase in the 
concentration of the agent that has been placed into the mobile phase [32]. 
2.3  Frontal analysis of drug-protein interactions 
Frontal analysis is one approach that has been employed in HPAC for drug-
protein interaction studies and work related to personalized medicine [21,43-51].  In this 
method, solutions containing known concentrations of a drug were continuously applied 
onto a given column.  As the solution of the target passes through the column, some or 
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most of the binding sites for this target in the column will become occupied by the drug.  
This process will lead to an increase in the amount of the target that elutes from the 
column over time. The mean position of each breakthrough curve for a given drug 
solution was then determined. The mean position of this curve was then fit to various 
models to determine the association equilibrium constants and the moles of binding sites 
for the drug on the column.   
For a system in which there is relatively fast association and dissociation between 
a drug (A) and an immobilized protein or binding agent (L), the following equations can 
be used to describe the response that would be expected for a system with a single type of 
binding site [52]. 
                                                𝑚𝐿𝑎𝑝𝑝 =
𝑚𝐿1𝐾𝑎1[𝐴]
(1+𝐾𝑎1[𝐴])
                                                         (2-2) 
                                  
1
𝑚𝐿𝑎𝑝𝑝
=
1
𝐾𝑎𝑚𝐿[A]
+
1
𝑚𝐿
                                                       (2-3) 
In Eqs. (2-2) and (2-3), mLapp refers to the moles of the applied drug that are required to 
reach the mean point of the breakthrough curve at a given concentration of the drug, [A].  
The association equilibrium constant and total moles of active binding sites for this 
interaction are described by the terms Ka and mL.  In Eq. (2-3) predicts that a single 
system should give a linear plot of 1/mLapp versus 1/[A], in which the value of mL can be 
obtained from the inverse of the intercept and Ka can be obtained from the ratio of the 
intercept over the slope.  
Similar models can be created for systems with two binding sites, as shown for a 
two-site model in Eqs. (2-4) and (2-5). 
                                        𝑚𝐿𝑎𝑝𝑝 =
𝑚𝐿1𝐾𝑎1[𝐴]
(1+𝐾𝑎1[𝐴])
+
𝑚𝐿2𝐾𝑎2[𝐴]
(1+𝐾𝑎2[𝐴])
                                        (2-4) 
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1
𝑚𝐿𝑎𝑝𝑝
=
1+𝐾𝑎1[𝐴]+𝛽2𝐾𝑎1[𝐴]+𝛽2𝐾𝑎1
2 [𝐴]2
𝑚𝐿{(𝛼1+𝛽2−𝛼1𝛽2)𝐾𝑎1[𝐴]+𝛽2𝐾𝑎1
2 [𝐴]2}
                          (2-5) 
These equations include two association equilibrium constants (Ka1 and Ka2), which show 
the higher and lower affinity in the column. The moles of these two types of sites are 
represented by mL1 and mL2. The α1 and β2 are the ratio of the moles of active binding 
sites high affinity site to all the active binding sites and the ratio of association 
equilibrium constants for the low versus high affinity sites.  
 One advantage of this method is that the equilibrium constant for the target with 
the binding agent can be determined at the same time as an estimate is obtained for the 
moles of binding sites that are present [21,43,53].  This makes this approach useful in 
examining the stoichiometry of a reaction and in comparing binding constants that are 
obtained from columns that may contain different amounts of the binding agent.  
However, this method can require large amounts of the target and, because of the number 
of experiments involved, does tend to take longer to carry out then some of the alternative 
methods that are described later in this thesis [43,54-55].   
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Figure 2-1. Structure of chlorpropamide, a typical sulfonylurea drug. The section in 
the dashed box shows the core structure of all sulfonylurea drugs. 
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Figure 2-2.  A typical HPLC system for use in zonal elution affinity chromatography 
and studies of solute-protein binding or solute-solute competition for 
proteins. 
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Figure. 2-3.  Typical chromatograms obtained in zonal elution studies using injections 
of R-warfarin as a site-selective probe for HSA and mobile phases that 
contained various concentrations of chlorpropamide as a competing agent 
or interacting agent. This figure was adapted and reproduced with 
permission from Ref. [42]. 
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Figure 2-4. Plots made according to Eq. (1-3) for various injected solutes – (a) 
digitoxin, (b) L-tryptophan, (c) R-warfarin and (d) tamoxifen – and mobile 
phases containing glimepiride that were applied to HSA columns. These 
plots represent systems in which there was (a)no interaction between the 
injected solute and agent in the mobile phase for binding sites in the 
column, (b) direct competition of these agents at a single type of common 
binding site, (c) negative allosteric effects between these agents during 
their binding to the column, or (d) positive allosteric effects as these agents 
were binding to the column. Behavior similar to that in (c) can also be 
produced by direct competition at multiple binding sites. This figure was 
adapted and reproduced with permission from Ref. [40]. 
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CHAPTER 3 
CHROMATOGRAPHIC STUDIES OF CHLORPROPAMIDE INTERACTIONS 
WITH NORMAL AND GLYCATED HUMAN SERUM ALBUMIN BASED ON 
AFFINITY MICROCOLUMNS 
Portions of this material have previously appeared in the following publication and are 
reproduced with permission: P. Tao, Z. Li, R. Mastuda, D.S. Hage, Chromatographic 
studies of chlorpropamide interactions with normal and glycated human serum albumin 
based on affinity microcolumns, J. Chromatogr. B 1097-1098 (2018) 64-73. 
 
3.1  Introduction 
            More than 360 million people in the world suffer from diabetes, and this number 
is expected to grow to 438 million by 2030 [1,2].  In the United States, an estimated 29.1 
million persons, or about 9% of the population, have been diagnosed with this disease 
[1,3].  Type I diabetes (or juvenile-onset diabetes) and type II diabetes (non-insulin 
dependent diabetes) account for 5-10% and 90%-95% of diabetic patients worldwide, 
respectively [2,3]. 
            Sulfonylurea drugs are often used in the treatment of type II diabetes [4,5].  The 
basic structure of a sulfonylurea drug is composed of a phenylsulfonyl group and a urea 
group.  Chlorpropamide is an oral first-generation sulfonylurea drug that has been used in 
the past to lower glucose levels in blood by stimulating insulin secretion [4-7].  The 
structure of this drug is given in Figure 3-1(a).  Like many other sulfonylurea drugs [8-
11], chlorpropamide is known to bind with more than one site on HSA or the related 
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protein bovine serum albumin (BSA); however, only a limited amount of previous work 
has been carried out in characterizing these interactions [5,12,14,15].  
            HSA has a normal concentration of 30–50 g/L and is the most abundant protein in 
serum or plasma.  This protein consists of a single chain of 585 amino acids and has a 
molar mass of 66.5 kDa [13].  HSA has two main drug-binding sites: Sudlow sites I and 
II [13,16-18].  Sudlow site I, which is present in subdomain IIA of HSA, binds to solutes 
and drugs such as salicylate and warfarin.  Sudlow site II is located in subdomain IIIA 
and binds to solutes and drugs such as L-tryptophan, ibuprofen, and ketoprofen, among 
many others [13,17,18].  It has been previously found that both these sites can bind to the 
first-generation sulfonylurea drugs acetohexamide and tolbutamide [8-11], as well as to 
several second- or third-generation sulfonylureas [19-22].  It has been further found 
through competition studies that chlorpropamide binds to at least Sudlow site I of HSA 
[12], although it is not known if Sudlow site II can also bind this drug.  
          The high levels of glucose that are present in blood during diabetes can result in the 
modification of proteins, including HSA [23-27].  This modification occurs through a 
process that is known as glycation [8,16,23-25], which is illustrated in Figure 3-1(b).  
Glycation is a non-enzymatic reaction during which glucose combines with an amine 
group on a protein to create a Schiff base; the Schiff base can then later rearrange to form 
a stable ketoamine, or Amadori product [8,16,25].  The glycation of proteins is linked to 
many of the long-term complications of diabetes [16].  This process has also been shown 
to alter the binding of some sulfonylurea drugs to HSA [8-11,25-27].  However, no 
previous studies have examined the effects of glycation on the interactions of 
chlorpropamide with HSA. 
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          Work in this chapter will combine the use of high-performance affinity 
chromatography (HPAC, also known as high-performance liquid affinity chromatography) 
with affinity microcolumns to examine the binding of chlorpropamide to normal HSA 
and glycated HSA.  HPAC is a type of liquid chromatography that uses an immobilized 
binding agent (e.g., HSA) as the stationary phase [28-30].  Advantages of HPAC with 
regards to the study of biological interactions include its ability to be automated and to 
provide relatively fast and precise results, while also allowing the same binding agent to 
often be used for hundreds of experiments [8-11,28-32].  HPAC has been used in prior 
work to examine the effects of HSA glycation on the binding of this protein to 
sulfonylurea drugs such as tolbutamide and acetohexamide [8-11].  It has been further 
shown in recent studies how affinity microcolumns with volumes in the low-to-mid 
microliter range can be employed with small amounts of a protein such as glycated HSA 
to rapidly provide a detailed characterization of how a target solute or drug interacts with 
this binding agent [8,33,34].   
            This chapter will use HPAC and affinity microcolumns to examine the overall 
binding of chlorpropamide to normal or glycated HSA and the specific interactions of 
this drug at Sudlow sites I and II.  The results will then be compared to those obtained 
previously for related sulfonylurea drugs [8-11,19-22].  These data should provide a 
clearer picture of how glycation can alter the binding of sulfonylureas to HSA during 
diabetes.  This work will produce fundamental information on how protein glycation, 
along with changes in the structure of sulfonylureas, may affect drug-protein interactions 
and illustrate how HPAC and affinity microcolumns can be employed as tools for a 
detailed analysis of these processes, as might be used for personalized medicine [8].    
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3.2  Experimental 
3.2.1.  Chemicals 
          The R-warfarin (≥ 97% pure), L-tryptophan (≥ 98%), HSA (product A1887, from 
human serum, essentially fatty acid free, ≥ 96%), and D-(+)-glucose (99.5%) and were 
from Sigma-Aldrich (St. Louis, MO, USA).  The chlorpropamide (≥ 99%) was purchased 
from Santa Cruz Biotechnology (Dallas, TX, USA).  The Nucleosil Si-300 (pore size, 
300 Å; particle size, 7 µm) was acquired from Macherey-Nagel (Duren, Germany).  The 
fructosamine assay was carried out using a kit from Diazyme Laboratories (San Diego, 
CA, USA).  The bicinchoninic acid (BCA) protein assay reagents were acquired from 
Pierce (Rockford, IL, USA).  Water that had been purified by a Milli-Q-Advantage A 10 
system (EMD Millipore, Billerica, MA, USA) was used to make all the aqueous solutions 
and mobile phases that were utilized in this research.  These solutions were filtered by 
passing them through 0.20 µm GNWP nylon membranes from Fisher Scientific 
(Pittsburgh, PA, USA). 
3.2.2.  Instrumentation 
            A Jasco (Tokyo, Japan) HPLC system was used in this report.  This system 
included the following components: two PU-2080 pumps; an AS-2057 autosampler; a 
DG-2080 degasser; a CO-2067 column oven; and a UV-2080 absorbance detector.  This 
system also employed a Rheodyne Advantage PF six-port valve (Cotati, CA, USA) and 
was controlled by LCNet and ChromNav software from Jasco.  The data from the 
chromatographic system were analyzed by using PeakFit 4.12 software from Jandel 
Scientific (San Rafael, CA, USA).  Regression and best-fit parameters for the data were 
acquired by using DataFit 8.169 (Oakdale, PA, USA).   
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3.2.3.  Glycation and modification of HSA 
            Two samples of glycated HSA (i.e., gHSA1 and gHSA2) were prepared in vitro 
as described previously under sterile conditions and using 1 mM sodium azide as a buffer 
additive to prevent bacterial growth [9,10,35].  This was done by using reaction mixtures 
made in pH 7.4, 0.067 M potassium phosphate buffer that contained a typical 
physiological concentration of normal HSA (42 g/L, using the same type of commercial 
preparation as employed in Section 2.4 when making the normal HSA microcolumns) 
and either 15 or 30 mM of D-glucose (i.e., as used to make gHSA1 or gHSA2 samples, 
which represented glucose levels that might be seen during controlled or advanced 
diabetes, respectively) [9,35].  These mixtures were incubated for about 4 weeks at 37 °C 
to allow glycation to occur, followed by use of a desalting column to remove the excess 
and unreacted glucose.  The glycated HSA samples were lyophilized and stored at -80 °C.  
A fructosamine assay was carried out on each HSA sample, in duplicate, to determine the 
level of glycation that was present [35].  The measured levels of glycation for the normal 
HSA, gHSA1, and gHSA2 samples were < 0.1, 1.40 (± 0.06), and 3.24 (± 0.07) mol 
hexose/mol HSA (Note: the values in parenthesis represent ± 1 S.D.).  
3.2.4. Column preparation 
            The supports used to make the affinity microcolumns were prepared by first 
modifying Nucleosil Si-300 into a diol-bonded form [36,37], with the HSA or glycated 
HSA then being immobilized to this material by the Schiff base method [36-38].  A 
control support was prepared in the same way but with no HSA being added as part of the 
immobilization process.  A BCA protein assay was employed, in triplicate, to determine 
the HSA content of each support, using soluble and normal HSA as the standard and the 
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control support as the blank.  The protein contents of these materials were found to be 89 
(± 3), 88 (± 6), and 91 (± 8) mg HSA/g silica for the normal HSA, gHSA1, and gHSA2 
supports.  
          These supports were placed into individual 1.0 cm × 2.1 mm i.d. stainless steel 
columns by using downward slurry packing at 3500 psi (24 MPa) and by utilizing a 
packing buffer that consisted of pH 7.4, 0.067 M potassium phosphate buffer.  These 
microcolumns contained 1.37-1.42 mg of normal HSA or glycated HSA, as determined 
by using the known packing density of the support (i.e., 0.45 g silica/cm3) and the 
support’s measured protein content.  Control microcolumns were packed in the same 
manner.  The microcolumns and any remaining supports were stored in the pH 7.4 buffer 
at 4 °C until use.  As has been noted in previous work [9-11,38], several hundred sample 
injections or applications could be made on the types of HSA supports and columns that 
were used in this study without appreciable changes being noted in their drug-protein 
binding properties.  For instance, a change in retention of less than 1.1% was seen in this 
work for R-warfarin on a normal HSA microcolumn over the course of almost 300 
injections and 18 months of use. 
3.2.5.  Chromatographic studies 
             The solutions of chlorpropamide, L-tryptophan, R-warfarin and sodium nitrate 
were prepared in pH 7.4, 0.067 M phosphate buffer, which was also used as the mobile 
phase for the chromatographic studies (Note: this buffer was selected because it has been 
routinely used in prior studies to examine binding by other sulfonylurea drugs with HSA) 
[9-11,34,38].  This buffer was passed through a 0.2 µm filter and degassed for 10-20 min 
prior to its use.  The solutions of R-warfarin were used within two weeks of preparation, 
32 
 
and the L-tryptophan solutions were used within 1-2 days, as based on previous studies 
examining the stability of such solutions [38-40].  All of the chromatographic 
experiments were performed at 0.30-0.50 mL/min and 37 °C.  The back pressure for the 
microcolumns under these conditions was 2.0 MPa (290 psi) or less.  As noted previously, 
no significant changes in the binding parameters that were measured in this work were 
seen when using other flow rates as long as sufficient time was still allowed for a local 
equilibrium to be established between the immobilized binding agent and the 
injected/applied drugs and probe compounds [8-11].     
            A six-port valve was used in the frontal analysis experiments to switch the mobile 
phase from the pH 7.4, 0.067 M phosphate buffer to the same buffer containing a known 
concentration of chlorpropamide.  The elution of chlorpropamide was detected at 250 nm.  
After a stable plateau had been reached in a frontal analysis experiment, the valve was 
switched to reapply the original pH 7.4 buffer to regenerate the column.  Frontal analysis 
was carried out on each column, including the control microcolumn and microcolumns 
containing normal HSA, gHSA1, or gHSA2, at ten concentrations of chlorpropamide 
spanning from 1.0 to 50.0 μM.  These drug concentrations gave a response in the linear 
range of the detector, and all measurements were made four times.  The mean position of 
each frontal analysis curve was found by using the first derivative function of PeakFit 
4.12 and were corrected for the void time by using sodium nitrate as a non-retained solute 
(see following paragraph). Over the range of drug concentrations that were employed, 
between 10 and 22% of the total binding for chlorpropamide was due to non-specific 
binding to the support on the normal and glycated HSA microcolumns, as has been noted 
for other first-generation sulfonylurea drugs [9-11].  The amount of bound drug that was 
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obtained for the control microcolumn at each drug concentration was either subtracted 
from the amount of bound drug on an HSA microcolumn at the same drug concentration 
or considered as part of binding models to correct for non-specific binding of 
chlorpropamide to the support [9-11,38].  
            The competition studies based on zonal elution were carried out by using R-
warfarin (i.e., a probe for Sudlow site I) and L-tryptophan (i.e., a probe for Sudlow site II) 
[35,38].  These studies were performed with eight different concentrations of 
chlorpropamide in the mobile phase, spanning from 0 to 20 μM.  The same solutions of 
chlorpropamide were used to make samples of the desired probe at a probe concentration 
of 5 µM (Note: the chlorpropamide was added to minimize changes in the local 
concentration of this drug in the mobile phase, and the corresponding changes in the 
background response during sample injection, as has been used in prior studies with other 
sulfonylurea drugs) [9-11,38].  The injection volume for all samples was 20 µL.  The 
probe samples were injected onto each type of microcolumn while the probe was 
monitored at 308 for R-warfarin or 280 nm for L-tryptophan.  A 20 µM solution of 
sodium nitrate, which was used as a non-retained solute for the HSA and glycated HSA 
supports [38], was also injected onto each microcolumn, as well as onto the 
chromatographic system with no microcolumn present; this solute was monitored at 205 
nm.  Each zonal elution experiment was carried out in quadruplicate, and the mean 
retention time of each peak was determined by using PeakFit 4.12.  
3.3.  Results and discussion  
3.3.1.  Overall binding of chlorpropamide with HSA 
3.3.1.1. General approach 
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          The overall interactions of chlorpropamide with normal and glycated HSA were 
examined by using frontal analysis [34,38].  These studies were carried out to provide an 
initial estimate for the number and types of sites (e.g., high vs. low affinity) that took part 
in these interactions; the higher affinity sites were of particular interest, as examined in 
more detail later through zonal elution (Section 3.3.2).  In the frontal analysis 
experiments, several solutions containing known concentrations of chlorpropamide were 
applied onto an HSA microcolumn or control microcolumn and used to obtain a series of 
breakthrough curves, as shown in Figure 3-2.  The mean breakthrough times for these 
curves occurred within 4-15 min of solution application at 0.30 mL/min (i.e., applied 
solution volumes of 1.2-4.5 mL) and when using a 1.0 cm × 2.1 mm i.d. column 
containing normal HSA.  The glycated HSA microcolumns exhibited similar behavior.  
Even shorter breakthrough times could be obtained with these microcolumns by using 
higher flow rates for sample application, but some loss in the precision of this method is 
known to occur as the flow rate is increased [41]. 
            The frontal analysis results were analyzed by looking at how the moles of 
chlorpropamide that were needed to reach the mean breakthrough time of each curve 
changed as the applied concentration of chlorpropamide was varied.  For instance, Eqs. 
(3-1) and (3-2) were used to represent a system with a single set of saturable sites and 
relatively fast association and dissociation between a drug (D) and an immobilized 
protein (or affinity ligand, L) [41-44]. 
1
 𝑚𝐿𝑎𝑝𝑝
=
1
𝐾𝑎𝑚𝐿[D]
+
1
𝑚𝐿
                                                      (3-1) 
𝑚𝐿𝑎𝑝𝑝 =
𝑚𝐿1𝐾𝑎1[D]
(1+𝐾𝑎1[D])
                                                          (3-2) 
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            In Eqs. (3-1), mLapp is the apparent binding capacity (i.e., moles of drug needed to 
reach the mean point of the breakthrough curve) of an immobilized protein at a given 
applied concentration for the drug [41].  Other terms in these equations include the 
association equilibrium constant (Ka) and moles of active sites for this interaction (mL).  
Eq. (3-1) indicates that a drug and protein with a one-site interaction should give a linear 
response for a plot of 1/mLapp versus 1/[D]; the value mL can be acquired from the 
reciprocal of the intercept for this plot, and Ka can be found by using the ratio of the 
intercept over the slope [41].  A non-linear fit to Eq. (3-2) can also be used to obtain these 
best-fit parameters [9-11,41-43].  An advantage of using frontal analysis and expression 
like Eqs. (3-2) is it allows separate estimates to be obtained for both the binding constants 
and moles of binding sites for an applied solute with an immobilized protein or binding 
agent [28,29,41].  However, no information is provided on the location of these binding 
regions [10,11,28,41]. 
             The presence of multiple sites that have significant differences in their affinity 
can be examined by using a suitably large range of drug/solute concentrations and 
alternative equations to those shown in Eqs. (3-2) [28,41].  An example of such an 
expression is shown in Eq. (3-3), which is a non-linear equation that describes a system 
with two groups of saturable sites for a drug with an immobilized binding agent (e.g., 
specific moderate-to-high affinity sites and non-specific lower affinity regions) [41,42].   
                                        𝑚𝐿𝑎𝑝𝑝 =
𝑚𝐿1𝐾𝑎1[D]
(1+𝐾𝑎1[D])
+
𝑚𝐿2𝐾𝑎2[D]
(1+𝐾𝑎2[D])
                                             (3-3) 
The terms Ka1 and Ka2 in this equation are the association equilibrium constants for the 
drug at a set of higher and lower affinity sites on the binding agent, while the moles of 
these sites are given by mL1 and mL2.  The double-reciprocal form of Eq. (3-3) is known to 
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give an apparent linear response for a plot of 1/mLapp versus 1/[D] when using low-to-
medium concentrations of the applied drug D, with negative deviations from this linear 
behavior occurring at high drug concentrations, or low values of 1/[D] [42,43].  
Furthermore, the slope from the linear region for this latter type of plot has been shown to 
provide a good initial estimate for Ka1 (i.e., the binding strength for the high affinity sites) 
in systems that follow a two-site interaction model [42]. 
            It is necessary when studying drug-protein binding by frontal analysis to correct 
for any secondary interactions the drug may have with the support [41].  This secondary 
binding can be examined by using frontal analysis to measure the amount of drug that is 
bound to a control column that contains the support but no immobilized protein.  One 
way this data can be used is to subtract the amount of drug that is bound to the control 
column from the total amount of drug that is bound to the protein column at the same 
drug concentration [9-11]; this provides an estimate for the value for mLapp in Eqs. (3-3).  
However, this correction method assumes the immobilized protein does not significantly 
alter the amount of binding the drug has with the support [45], which may not be true for 
supports that have a high protein content.   
            An alternative approach is also possible for correcting for these secondary 
interactions, and that does not assume they are constant in the presence of an 
immobilized protein.  This can be done by fitting the frontal analysis data for the control 
column to a binding model to estimate the total moles of sites for the drug on the support 
(mS) and the association equilibrium constant of the drug at these sites (KaS).  These 
parameters can then be used with expanded versions of the one-site and two-site 
drug/protein models in Eqs. (3-2, 3-3) that now include an additional binding term for the 
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support.  Examples of these expanded equations are provided in Eqs. (3-4, 3-5), in which 
the total moles of drug that is bound to each protein column, including secondary binding 
to the support, is represented by the term mLapp,tot. 
                                 𝑚𝐿𝑎𝑝𝑝,𝑡𝑜𝑡 =
𝑚𝐿1𝐾𝑎1[D]
(1+𝐾𝑎1[D])
+  
α 𝑚𝑆𝐾𝑎𝑆[D]
(1+𝐾𝑎𝑆[D])
                                             (3-4) 
                           𝑚𝐿𝑎𝑝𝑝,𝑡𝑜𝑡 =
𝑚𝐿1𝐾𝑎1[D]
(1+𝐾𝑎1[D])
+
𝑚𝐿2𝐾𝑎2[D]
(1+𝐾𝑎2[D])
+ 
α 𝑚𝑆𝐾𝑎𝑆[D]
(1+𝐾𝑎𝑆[D])
                                (3-5) 
            Because the values of mS and KaS are determined separately for the control column, 
the only additional fitted parameter in going from Eqs. (3-2, 3-3) to Eqs. (3-4, 3-5) is the 
term α.   This term, which should have a value between zero and one, represents the 
fraction of the original support’s surface or binding sites that is still accessible to the drug 
after protein immobilization.   
            Both of these approaches for considering secondary interactions were employed at 
various stages in this study.  Similar trends and binding constants for chlorpropamide 
with HSA were obtained by each approach (see Section 3.3.1.2).  However, the final 
results given in Section 3.3.1.2 were obtained by using Eqs. (3-4, 3-5).  It was determined 
in these equations that the presence of HSA did lead to a decrease in the amount of 
secondary binding between chlorpropamide and the support.  For instance, Table 3-1 
shows that the term α was equal to 0.40-0.42 when using Eq. (3-5) to fit the frontal 
analysis data for the HSA microcolumns to a two-site drug/protein binding model.  This 
indicated that up to 58-60% of the support’s secondary sites were no longer accessible to 
chlorpropamide once HSA had been immobilized to this material. The average precision 
for the overall moles of bound drug that were measured and used in these fits was ± 2.2% 
(range, ± 0.2-6.7%) under the concentration, column size, and flow rate conditions that 
were employed. 
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3.3.1.2. Interactions of chlorpropamide with normal and glycated HSA  
            Figure 3-3 shows the best-fit results that were obtained for chlorpropamide on 
microcolumns containing normal HSA or gHSA2 and when using a one-site model with a 
double-reciprocal plot based on Eq. (3-1) (Note: these particular results used a simple 
subtraction of the HSA and control column data to correct for binding by the drug to the 
support).  The column containing gHSA1 gave similar behavior to that seen in Figure 3-3.  
These plots appeared initially to give a good fit to Eq. (3-1) over the range of drug 
concentrations that were studied, with correlation coefficients for these fits that ranged 
from 0.9996 to 0.9998 (n = 10).  However, a closer examination of these results did 
indicate that some slight negative deviations from a linear response may have been 
present for the higher drug concentrations that were examined, as can be seen at the lower 
left portion of Figure 3-3(b).  Thus, linear fits were also made to only the data obtained at 
lower drug concentrations (i.e., 1.0 to 7.5 µM, in this case), as based on Ref. [42,43].  
These latter plots gave correlation coefficients that ranged from 0.9998 to 0.9999 (n = 5).    
            The linear fits of double-reciprocal plots to both the entire data set and data 
obtained at lower drug concentrations, with the latter emphasizing the strongest 
interaction sites, were used to estimate the value of Ka1 for the higher affinity sites of 
chlorpropamide on the various types of HSA microcolumns.  The resulting estimates that 
were obtained for chlorpropamide with normal HSA from the entire data set and the data 
at lower drug concentrations were 4.3 (± 0.3) × 104 M-1 and 3.5 (± 0.6) × 104 M-1, 
respectively; this was equivalent to dissociation equilibrium constants (Kd, where Kd = 
1/Ka) of 2.3 (± 0.2) × 10
-5 M and 2.9 (± 0.5) × 10-5 M.  The corresponding estimates of 
Ka1 that were obtained for chlorpropamide with microcolumns containing gHSA1 were 
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4.9 (± 0.2) × 104 M-1 and 4.9 (± 0.4) × 104 M-1, or Kd values of 2.0 (± 0.1) × 10
-5 M and 
2.0 (± 0.2) × 10-5 M.  The Ka1 values for the microcolumn containing gHSA2 were 5.6 (± 
0.4) × 104 M-1 and 6.8 (± 0.3) × 104 M-1, giving values for Kd of 1.8 (± 0.1) × 10
-5 M and 
1.5 (± 0.1) × 10-5 M.  The best estimates for the highest affinity sites for gHSA1 and 
gHSA2, as obtained from the lower drug concentration data, were 1.40-fold to 1.94-fold 
higher than the estimate of Ka1 that was obtained for normal HSA, with each of these 
changes being significant at the 95% confidence level.  These changes indicated that the 
glycation of HSA did have an effect on the binding of chlorpropamide with at least some 
regions on this protein.   
            The same data were analyzed in more detail by using non-linear regression and 
one-site or two-site models, with a simultaneous correction for binding the support as 
based on Eqs. (3-4) or Eq. (3-5).  Figure 3-4 shows how these two types of models fit 
with the experimental data, as demonstrated by using the results obtained for 
chlorpropamide on a normal HSA microcolumn.  Similar trends were seen for the 
glycated HSA microcolumns.  The one-site model gave lower correlation coefficients 
than the two-site model, with values that ranged from 0.9489-0.9856 and 0.9993-0.9997, 
respectively (n = 11).  In addition, the two-site model gave a more random distribution of 
the data about the best-fit lines.  The use of higher-order models did not improve the fit of 
these data sets any further.  These results, along with the deviations from linearity seen 
for some of the plots made according to Eq. (3-1), suggested that the two-site model gave 
a better description than the one-site model for the interactions between chlorpropamide 
and normal HSA or glycated HSA.  The same observation has been made for other first-
generation sulfonylurea drugs [8-11] and in previous binding studies between 
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chlorpropamide and normal HSA or BSA [14,15]. The best-fit parameters that were 
obtained with both the one- and two-site models for HSA, including the parameters used 
to correct for binding by chlorpropamide to the support, are summarized in Table 3-1.  
The overall association equilibrium constants that were obtained for chlorpropamide at 
pH 7.4 and 37ºC with normal HSA and glycated HSA varied from 3.5 to 4.7 × 104 M-1 
when using a one-site model for HSA and, for the higher affinity sites, ranged from 6.2 to 
9.9 × 104 M-1 when using a two-site model for HSA.  The corresponding values for Kd 
ranged from 2.9 to 2.1 × 10-5 M for the one-site model and from 1.6 to 1.0 × 10-5 M for 
the higher affinity sites in the two-site model.  The overall Ka values that were obtained 
were consistent with a value of 0.99 × 10-5 M for n1Ka1 (where n is the number of a given 
type of site per protein), as calculated based on prior data reported at pH 7.4 and 37ºC for 
the high affinity site of chlorpropamide with normal HSA in solution [14].  The range of 
these values for chlorpropamide also agreed with the overall or high affinities of 12 to 20 
× 104 M-1 and 8.4 to 12 × 104 M-1 that have been observed for acetohexamide and 
tolbutamide with normal HSA and similar samples of glycated HSA [9-11].  The 
precisions of these values varied from ± 8.5-17% (average, ± 13.0%) for Ka1 in the one-
site model and from ± 6.5-9.1% (average, ± 7.8%) for Ka1 in the two-site model.  The 
number of the high affinity sites per HSA molecule (i.e., as based on the measured 
content of HSA in the microcolumns and the values for mL1 when using the two-site 
model) was 0.12 to 0.18 (average, 0.15).  Given that not all of the immobilized HSA was 
active [9-11,37,38], these results indicated that only one or a few binding regions on HSA 
probably made up the higher affinity sites for chlorpropamide, as suggested in a prior 
solution-phase studies [14].  The number of lower affinity sites (e.g., with Ka2 values of 
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1.8 to 5.7 × 103 M-1 and representing weak or non-specific binding regions on HSA) was 
less well-defined but was determined in the same manner to range from at least 2.1 to 7.0 
(average, 5.0).  This latter result was also consistent with previous solution-phase binding 
studies that have been conducted between chlorpropamide and normal HSA or BSA 
[14,15]. 
            With both the one-site and two-site models, there was an increase in the overall 
affinity of chlorpropamide when going from normal HSA to the samples of glycated 
HSA, as discussed earlier.  This increase was 1.29- to 1.34-fold when using the one-site 
model and 1.44- to 1.60-fold for the estimated binding strength of the high affinity sites 
in the two-site model.  Each of these changes was significant at the 95% confidence level.  
It has been suggested in work with other sulfonylurea drugs and through structural 
characterization based on mass spectrometry that these changes in affinity are a result of 
glycation-related modifications that occur at or near the various drug binding regions of 
HSA, including Sudlow sites I and II [8-11,25,44-48]. 
3.3.2.  Site-selective binding of chlorpropamide with HSA 
3.3.2.1. General approach 
 Zonal elution was next used to provide a more detailed examination of how the 
binding of chlorpropamide changed at Sudlow sites I or II of HSA as a result of glycation.  
This was done by using a competition study, in which a site-specific probe (e.g., R- 
warfarin or L-tryptophan) was injected onto an HSA or glycated HSA microcolumn as a 
solution of chlorpropamide with a known and constant concentration was passed through 
the same microcolumn.  Figure 3-5 shows some typical chromatograms from these 
experiments.  The elution of the probe compounds occurred within 6 min or less when 
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using an injection flow rate of 0.50 mL/min.  The retention time for each injected 
probe was measured as the concentration of the chlorpropamide was varied, and 
the corresponding value of the probe’s retention factor (k) was calculated for each 
mobile phase that was employed.  
          It is known from prior work with this type of experiment that if the injected probe 
and drug in the mobile phase have a single site of competition, a plot made of 1/k versus 
the molar drug concentration, [D], should follow the linear relationship that is given by 
Eq. (3-6) [28,34,41].  Examples of such plots are provided in Figure 3-6.   
1
  𝑘
=
𝐾𝑎D𝑉𝑀[D]
𝐾𝑎P𝑚𝐿
+
𝑉𝑀
𝐾𝑎P𝑚𝐿
                                                (3-6) 
            The association equilibrium constants for the probe and drug at their site of 
competition are represented in Eq. (3-6) by KaP and KaD, while VM is the void volume, 
and mL is the moles of the common binding sites the probe and drug have in the column.  
If competition occurs between the drug and probe at a single common site, the ratio of the 
slope versus intercept for a plot made according to this equation should provide the local 
association equilibrium constant for the drug at this common site [28,34,41].  One 
advantage of this approach is it provides a value for KaD that is independent of the moles 
of active protein or binding sites in the column [41].  This value is also independent of 
any other interaction regions the applied drug may have with the immobilized binding 
agent or with the support as long as the injected probe does not interact with these other 
regions [28,41], as has been noted to be the case in prior work with the site-selective 
probes that were employed in this study (i.e., R-warfarin and L-tryptophan) 
[28,35,38,40,44]. 
3.3.2.2.  Competition studies at Sudlow site I 
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      Competition studies were first carried out by using zonal elution experiments and 
R-warfarin as a probe for Sudlow site I [35,38,44,49].  This site was of interest because it 
has been suggested through prior competition studies to be a binding region for 
chlorpropamide on HSA [12].  Furthermore, this region is known to bind other first-
generation sulfonylurea drugs [8-11].  The data from zonal elution competition studies 
that used R-warfarin as a probe gave a linear plot for each type of HSA microcolumn 
when the data were examined by using Eq. (3-6), as illustrated in Figure 3-6(a).  The 
correlation coefficients for these lines spanned from 0.9758 to 0.9930 (n = 8).  This 
behavior confirmed that chlorpropamide had direct interactions with R-warfarin and 
binding at Sudlow site I on normal HSA and glycated HSA.  The average precision of the 
retention factors that were obtained in these measurements was ± 1.2% (range, ± 0.2-
4.1%). Table 3-2 lists the association equilibrium constants that were acquired by this 
method at Sudlow site I for chlorpropamide on the normal HSA and glycated HSA 
microcolumns.  These values were in the general range of 3.9-4.7 × 104 M-1 at pH 7.4 and 
37ºC (i.e., Kd values of 2.6 to 2.1 × 10
-5 M), with precisions of ± 5.1-10.6% (average, ± 
8.4%).   
          These binding constants were consistent with the general estimates of 3.4-9.6 × 104 
M-1 that had been obtained by frontal analysis in Section 3.3.1 for the higher affinity 
regions of chlorpropamide with normal or glycated HSA.  Previous competition studies 
that were conducted at pH 7.0 and a lower temperature of 25ºC gave an estimated binding 
constant of 2.9 × 105 M-1 for chlorpropamide at Sudlow site I of normal HSA [12]; 
however, it is known that the binding strength of drugs with HSA tends to decrease with 
an increase in temperature [28].  For instance, a decrease in affinity of 20-30% has being 
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observed at pH 7.4 for R/S-warfarin at Sudlow site I when going from 25 to 37ºC [44], 
and a decrease of 21% in affinity for the strongest binding sites has been reported for 
chlorpropamide with BSA in going from 15 to 30ºC [15]. The values shown in Table 3-2 
for chlorpropamide were in the same general range as binding constants of 3.8-5.9 × 104 
M-1 and 5.5-6.9 × 104 M-1 that have been measured at Sudlow site I at pH 7.4 and 37ºC 
for acetohexamide and tolbutamide, respectively, with normal HSA and samples of 
glycated HSA like those used in this report [9-11].  Chlorpropamide gave a binding 
constant at Sudlow site I that was 29% weaker than seen for tolbutamide with normal 
HSA, with similar decreases of 28-35% being seen in the binding strength for glycated 
forms of HSA [9,11].  The two differences in the structures of tolbutamide and 
chlorpropamide, as shown in Table 3-1(a), are the change from a methyl group to a 
chlorine on the phenyl ring (R1) and a change from a butyl group to a propyl group at the 
other end of the structure (R2).  Given that Sudlow site I is known to prefer compounds 
with bulky heterocyclic structures [13,17,18], it is the change on the phenyl group that is 
probably responsible for most of the decrease in binding strength for chlorpropamide vs. 
tolbutamide at this site for both normal and glycated HSA.  This observation is consistent 
with the much smaller change noted in binding strength between chlorpropamide and 
acetohexamide, with a 7% decrease for chlorpropamide for normal HSA and a 13-15% 
increase for glycated HSA [10,11].  For these latter two compounds, there is a change 
from a chlorine to an acetyl group on the phenyl ring at R1 and a change from a propyl 
group to a cyclohexyl group at R2, neither of which appears to have led to any major 
differences in the binding of these two drugs to Sudlow site I.     
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           The effect of glycation on the site-specific affinities measured at Sudlow site I 
were consistent with the patterns seen in Section 3.1 for the overall affinities or higher 
affinity constants for chlorpropamide with HSA.  For instance, there was an apparent 
1.10-fold increase in the binding strength for chlorpropamide at Sudlow site I in going 
from normal HSA to gHSA1 and an increase of 1.21-fold in going from normal HSA to 
gHSA2.  Although these differences were relatively small and approached the level of 
precision for the zonal elution measurements, the results for gHSA2 were significant at 
the 95% confidence level.  As stated in Section 3.1, such changes in binding strength with 
glycation are believed to reflect the different amounts and types of modification that 
occur on HSA as its level of glycation is increased [8-11,46-48,50].  Examples of specific 
modification sites due to glycation that have been found to occur at or near Sudlow site I 
include K199, K281, and K276 [25].   
2.3.2.3. Competition studies at Sudlow site II  
 Zonal elution and competition studies were further used to examine the 
interactions of chlorpropamide at Sudlow site II by using L-tryptophan as a site-selective 
probe for this region [28,38,40,51].  This site was of interest because it has been found to 
bind to other first-generation sulfonylurea drugs such as acetohexamide and tolbutamide 
[8-11].  The results for these experiments when chlorpropamide was added to the mobile 
phase gave a linear plot for both the normal and glycated HSA microcolumns when the 
data were plotted according to Eq. (3-6), as shown by the example in Figure 3-6(b).  
These plots had correlation coefficients that ranged from 0.8877 to 0.9546 (n =7-8).  
These results indicated that chlorpropamide had direct interactions at Sudlow site II on 
normal or glycated HSA, in addition to the binding that occurred at Sudlow site I.  The 
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retention factors used to generate these plots had an average precision of ± 3.8% (range, 
± 0.2-18%). 
 Table 3-2 includes the association equilibrium constants measured at Sudlow site 
II during the zonal elution experiments for chlorpropamide with normal HSA or the 
samples of glycated HSA.  These values were in the range of 2.0-3.1 × 104 M-1 at pH 7.4 
and 37ºC (i.e., Kd values of 5.0 to 3.2 × 10
-5 M) and had precisions of ± 14-20% (average, 
± 18%).  The results were also only slightly lower than the estimated binding constants of 
3.9-4.7 × 104 M-1 that were acquired in the previous section for chlorpropamide at 
Sudlow site I on the same microcolumns.  In addition, these values were of the same 
order of magnitude, but lower than, binding constants for Sudlow site II of 7.9-13 × 104 
M-1 and 5.3-7.2 × 104 M-1 that have been reported at pH 7.4 and 37ºC for acetohexamide 
and tolbutamide with normal HSA and comparable preparations of glycated HSA [9-11] 
The binding constant for chlorpropamide at Sudlow site II was 63% lower than seen for 
tolbutamide with normal HSA; similar decreases of 52-61% were observed in the binding 
constants for glycated HSA [9,11].  Sudlow site II is known to interact with aromatic 
carboxylic acids and related compounds [13,17,18], so these changes in binding were 
again mostly likely due to the change from a methyl group to a chlorine group at R1.  It is 
interesting to note that this alteration in structure produced a much larger change than 
was seen at Sudlow site I, with normal and glycated HSA having similar patterns in their 
relative binding strengths for chlorpropamide vs. tolbutamide.  A large decrease in 
relative binding strength was further seen when comparing chlorpropamide with 
acetohexamide, with chlorpropamide giving an 85% lower affinity at Sudlow site II for 
normal HSA and 74-75% lower values for glycated HSA [10,11].  These differences 
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were also thought to be primarily the result of changes in structure at R1, although some 
additional contributions from the changes at R2 may have been present. As was seen for 
Sudlow site I, glycation again resulted in an increase in the affinity of chlorpropamide at 
Sudlow site II and at the levels of modification employed in this report.  In this case, 
there was a 1.40-fold increase in the affinity for chlorpropamide at Sudlow site II in 
going from normal HSA to gHSA1 and an increase of 1.55-fold in going from normal 
HSA to gHSA2, with all of these differences being significant at the 95% confidence 
level and larger than the relative uncertainty expected due to only random errors.  These 
changes in binding were again probably a result of the different amounts and types of 
glycation-related modifications that occurred on these HSA samples [8-11,47,48,50].  For 
instance, K439 is one major glycation site that occurs at Sudlow site II of HSA [25].    
3.4  Conclusion 
            HPAC was used in this work to investigate the binding of chlorpropamide, a first-
generation sulfonylurea drug, to normal HSA and HSA with levels of glycation 
corresponding to controlled or advanced diabetes.  Frontal analysis was first used to 
examine the overall binding of chlorpropamide with normal and glycated HSA.  
Although a one-site model gave a reasonable fit to the binding data for these interactions, 
a slightly better fit was obtained when using a two-site model based on a set of moderate-
to-high affinity sites (i.e., the equivalent of two sites with overall binding constants 
around 6.2-9.9 × 104 M-1 at pH 7.4 and 37ºC) and a set of lower affinity binding sites 
(binding constants, 1.8-5.7 × 103 M-1).  This type of behavior and observed range of 
affinities were consistent with interaction models that have been reported for tolbutamide 
and acetohexamide, two other first-generation sulfonylurea drugs, with normal HSA and 
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similar preparations of glycated HSA [8-11].  A net increase in the overall binding 
strength of chlorpropamide for the higher affinity sites of up to 1.6-fold was noted when 
comparing the glycated HSA samples to normal HSA.  
            Zonal elution-based competition studies were used to provide more site-specific 
information on the interactions between chlorpropamide at Sudlow sites I and II of 
normal HSA or glycated HSA.  This drug was found to bind to both Sudlow sites I and II, 
as has been noted for other first-generation sulfonylurea drugs [6-9].  Glycation levels 
like those found in controlled or advanced diabetes gave a slight increase in the binding 
strength of chlorpropamide at Sudlow site I by up to 1.2-fold and a larger increase at 
Sudlow site II of 1.4- to almost 1.5-fold, when compared to the binding observed for 
normal HSA.  These changes both contributed to the overall increase in affinity of 
chlorpropamide that was noted for the same glycated HSA samples.  A comparison of 
these results with those of closely-related drugs made it further possible to examine the 
role played by the side groups in these compounds in altering their interactions at Sudlow 
sites I and II.     
            This work demonstrated several potential advantages in using affinity 
microcolumns for examining drug-protein interactions.  The small size of the affinity 
microcolumns made it possible to carry out detailed binding studies in a matter of 
minutes and under isocratic conditions for interactions that had affinities up to 105 M-1.  
In addition, only a small amount of HSA was required per column (i.e., about 1.4 mg), 
making it practical to use this approach with modified forms of HSA.  Each column could 
also be used for many binding studies.  For instance, a single affinity microcolumn was 
used in this study for over 300 sample injections or application cycles, which was the 
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equivalent of using less than 5 µg HSA per experiment.  The good long-term stability of 
these columns, the use of these microcolumns in an HPLC system, and the ability to 
reuse the same immobilized protein made it possible to obtain binding constants with 
good precisions and to examine even relatively small shifts in binding strength that 
occurred for chlorpropamide with glycated versus normal forms of HSA.   
          The approach used in this study is not limited to glycated HSA but could be 
employed in binding studies with other modified proteins or even proteins that have been 
isolated from individual clinical samples [8,52].  The advantages of affinity 
microcolumns in this type of research should make them useful in future interaction 
studies of additional solute-protein systems and as tools for personalized medicine in 
examining the changes in protein binding and function that may occur in diseases such as 
diabetes. 
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Figure 3-1.  (a) Structures of the first-generation sulfonylurea drugs chlorpropamide 
(i.e., 1-[(p-chlorophenyl)sulfonyl]-3-propylurea)), tolbutamide and 
acetohexamide; (b) the addition of glucose to an amine group on a protein 
through the process of glycation.  The dashed box in (a) shows the core 
structure of a sulfonylurea drug.  The reactions in (b) represent the 
formation of an early stage glycation product; further reactions can occur 
to form advanced glycation end-products (AGEs) [23].   
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Figure 3-2. Typical chromatograms obtained by frontal analysis for the application of 
chlorpropamide to a 1.0 cm × 2.1 mm i.d. column containing normal HSA 
column.  The concentrations of the applied drug are shown on the right.  
The flow rate was 0.30 mL/min.  These studies were performed at 37°C 
and pH 7.4.  
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Figure 3-3.  Double-reciprocal plots made according to Eq. (3-1) to examine data 
obtained for the binding of chlorpropamide with (a) normal HSA and (b) 
glycated HSA2 during frontal analysis studies.  The best-fit lines shown 
are for the lower concentration data (i.e., 1.0 to 7.5 µM) and had 
correlation coefficients of 0.9998-0.9999 (n = 5).  The error bars represent 
a range of ± 1 S.D. 
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Figure 3-4.  Comparison of the fits for (a) one-site and (b) two-site models to frontal 
analysis data for the overall binding of chlorpropamide to a column 
containing normal HSA.  These fits were obtained by using Eqs. (3-4) and 
(3-5), respectively.  The insets show the corresponding residual plots.  The 
relative standard deviations for the values of mLapp,tot that are shown in 
these plots ranged from ± 0.17% to ± 4.7% (average, ± 2.0%). 
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Figure 3-5.  Typical chromatograms obtained by zonal elution competition studies on a 
1.0 cm × 2.1 mm i.d. column containing normal HSA and for the injection 
of R-warfarin in the presence of application of mobile phases that 
contained 20 or 0 µM chlorpropamide.  The flow rate was 0.50 mL/min.  
These studies were performed at 37°C and pH 7.4. 
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Figure 3-6.  Example of plots made according to Eq. (3-6) when using chlorpropamide 
as a competing agent in the mobile phase and (a) R-warfarin or (b) L-
tryptophan as the injected probe on a column containing glycated HSA1.  
The best-fit lines in (a) and (b) had correlation coefficients of 0.9813 and 
0.9546, respectively.  The error bars represent ± 1 S.D. 
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Table 3-1.  Best-fit parameters based on one- or two-site models for the overall 
binding of chlorpropamide with normal HSA or glycated HSAa 
Type of HSA 
& binding 
model 
Ka1  
(M-1 × 104) 
mL1  
(mol × 10-9) 
Ka2  
(M-1 × 104) 
mL2  
(mol × 10-8)     
α 
 One-site model      
Normal HSA 3.5 (± 0.3) 16.5 (± 0.7) ------ ------ 0.48 (± 0.12) 
gHSA1 4.5 (± 0.6) 15.9 (± 0.9) ------ ------ 0.49 (± 0.19) 
gHSA2 4.7 (± 0.8) 15.7 (± 1.3) ------ ------ 0.48 (± 0.31) 
Two-site model      
Normal HSA 6.2 (± 0.4) 3.4 (± 0.3)  0.57 (± 
0.10) 
4.3 (± 0.6) 0.42 (± 0.02) 
gHSA1 8.9 (± 0.7) 3.7 (± 0.3)  0.18 (± 
0.01) 
12.4 (± 7.1) 0.41 (± 0.03) 
gHSA2 9.9 (± 0.9) 2.4 (± 0.2)  0.19 (± 
0.06) 
14.8 (± 0.3) 0.40 (± 0.01) 
 
aThese results were measured at 37 °C in the presence of pH 7.4, 0.067 M potassium 
phosphate buffer.  The values in parentheses represent a range of ± 1 S.D.  The 
parameters shown for the one-site and two-site binding of chlorpropamide with HSA 
were obtained by using Eqs. (4) and (5), respectively, along with independently-estimated 
values for KaS and mLS of 1.64 × 10
4 M-1 and 8.6 × 10-9 mol. 
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Table 3-2.  Site-specific association equilibrium constants (Ka) for the interactions of 
chlorpropamide at Sudlow sites I and IIa 
 
Type of HSA 
Sudlow site I 
Ka (M-1× 104) 
Change vs.  
normal HSA 
Sudlow site II 
Ka (M-1× 104) 
Change vs.  
normal HSA 
Normal HSA 3.9 (± 0.2) × 104 ------ 2.0 (± 0.4) × 104 ----- 
gHSA1 4.3 (± 0.4) × 104 ↑ 1.10-fold (N.S.)b 2.8 (± 0.4) × 104 ↑ 1.40-fold 
gHSA2 4.7 (± 0.5) × 104 ↑ 1.21-fold 3.1 (± 0.6) × 104 ↑ 1.55-fold 
 
aThese results were measured at 37 °C in the presence of pH 7.4, 0.067 M potassium 
phosphate buffer.  The values in parentheses represent a range of ± 1 S. D.   
bMost of the changes shown in this table for gHSA1 and gHSA2 vs. normal HSA were 
significant at the 95% confidence level.  The exception was the change seen at Sudlow 
site I for gHSA1 vs. normal HSA, which was not significant (N.S.) at the 95% confidence 
level but was significant at the 90% confidence level. 
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CHAPTER 4 
CHROMATOGRAPHIC STUDIES OF TOLAZAMIDE INTERACTIONS WITH 
NORMAL AND GLYCATED HUMAN SERUM ALBUMIN BASED ON 
AFFINITY MICROCOLUMNS 
Portions of this material have previously appeared in the following publication and are 
reproduced with permission: P. Tao, Z. Lia, A. Woolfork, D.S. Hage, Chromatographic 
studies of tolazamide binding with glycated and normal human serum albumin by using 
high-performance liquid chromatography, J. Pharm. Biomed. Anal. 166 (2019) 273-280. 
 
4.1 Introduction 
As described in Section 3.1, sulfonylurea drugs are frequently used to treat type II 
diabetes.  Like other compounds in this group, tolazamide is known to have a moderately 
strong interaction with the transport protein human serum albumin (HSA) and the 
closely-related protein bovine serum albumin (BSA) [1-9].  Prior work has suggested that 
either one or two groups of sites are involved in the binding of tolazamide to serum 
albumin [2,3]. High-performance affinity chromatography (HPAC) will be utilized in this 
study to examine the interactions between tolazamide and HSA at various levels of 
glycation.  Frontal analysis and zonal elution will be utilized in this chapter with HPAC 
to investigate the overall binding and site-specific interactions of normal and in vitro 
glycated forms of HSA with tolazamide. This study will also include a comparison 
between these results and prior observations made for alternative first-generation 
sulfonylurea drugs to see how alterations in the structure of these compounds affect their 
binding to HSA and glycated HSA [2-9].  The final results should provide a better 
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understanding of the effects of HSA glycation on the transport and protein binding by 
sulfonylurea drugs in serum.  These data should also provide useful information for 
future applications in the field of personalized medicine, as pertaining to the ability to 
adjust a drug dosage for a given patient in a disease such as diabetes [4]. 
4.2  Experimental 
4.2.1  Chemicals 
The HSA (lyophilized powder, essentially fatty acid free, ≥ 96% pure), L-
tryptophan (≥ 98%), R-warfarin (≥ 97% pure), D- (+)-glucose (99.5%), and sodium azide 
(>95%) were purchased from Sigma Aldrich (St. Louis, MO, USA).  The tolazamide (≥ 
99% pure) was from Santa Cruz Biotechnology (Dallas, TX, USA).  Modification levels 
of the in vitro glycated HSA samples were measured using a fructosamine kit purchased 
from Diazyme Laboratories (San Diego, CA, USA), and the protein content of each 
chromatographic support was measured using a bicinchoninic acid assay (BCA) from 
Pierce (Rockford, IL, USA).  All aqueous solutions were prepared using purified water 
from a Milli-Q-Advantage A 10 system (EMD Millipore, Billerica, MA, USA); these 
solutions were filtrated through 0.20 µm GNWP nylon membranes (Fisher Scientific, 
Pittsburgh, PA, USA). 
4.2.2      Instrumentation 
The same Jasco HPAC system was used for this work as described in Section 
3.2.2. 
4.2.3  Preparation of glycated HSA 
Glycated samples of HSA (i.e., gHSA1 and gHSA2) were made in vitro by using 
a prior method, as described in Section 3.2.3 [5-7]. 
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4.2.4  Preparation of HSA microcolumns 
In this study, the affinity microcolumns were prepared by following same 
procedures as described in Section 3.2.4. 
4.2.5  Chromatographic studies  
All drug solutions were prepared in phosphate buffer (pH 7.4, 0.067 M) and 
filtered through a 0.2 µm membrane, followed by degassing for 10-20 min. The L-
tryptophan solutions were prepared fresh daily, while the R-warfarin solutions where 
prepared and used within two weeks [10-12].  The chromatographic experiments were 
conducted at 37 °C and 0.50 mL/min, as employed in previous drug-binding studies using 
similar protein supports or columns [4-9].   
Frontal analysis studies were conducted by applying a potassium phosphate buffer 
(pH 7.4, 0.067 M) onto a microcolumn until a steady baseline was obtained.  A step 
change was then made for the application of a known concentration of tolazamide, as 
prepared in the same buffer and passed continuously through the microcolumn.  A total 
of 12 solutions containing 0.5 to 50 μM tolazamide were applied in triplicate to each 
HSA microcolumn and control microcolumn.  After reaching a stable plateau at a given 
concentration of tolazamide, the original buffer was then reapplied to the microcolumn to 
elute the bound tolazamide and regenerate the system.  The elution of tolazamide was 
detected at a wavelength of 254 nm, and all concentrations of this drug that were 
examined were within the linear range of the detector at this wavelength.  The first 
derivative function in PeakFit 4.12 was used to find the mean position of each frontal 
analysis (or breakthrough) curve.  Identical studies were conducted on a control column 
to correct for the system void time and non-specific binding of tolazamide to the support, 
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as has been used in previous work with similar support materials and columns [4-10].  
The relative extent of non-specific binding ranged from 27-36% of the total measured 
binding on the HSA microcolumns over the range of tolazamide concentrations that were 
examined; these results are in line with previous data that have been acquired with 
another first-generation sulfonylurea drugs (i.e., chlorpropamide) on similar columns [9].   
Zonal elution competition studies were conducted by employing R-warfarin and 
L-tryptophan as site specific probes for HSA [10].  Eight mobile phase concentrations 
prepared in phosphate buffer (pH 7.4, 0.067 M) and ranging from 0 to 20 μM tolazamide 
were used in these experiments. Each sample contained 5 µM of the given probe, as 
prepared in the mobile phase.  A 20 µL portion of each sample was injected (four times) 
under each set of mobile phases and microcolumn conditions.  The wavelengths that were 
utilized for detection were 308 and 280 nm for R-warfarin and L-tryptophan, respectively.  
A 20 µM solution of sodium nitrate in phosphate buffer (pH 7.4, 0.067 M) was used as a 
void volume marker and was monitored at 205 nm.  Zonal elution experiments were 
performed in replicate (four times), and an exponentially-modified Gaussian curve fit was 
used to find the mean retention time of each peak.  
4.3  Results and discussion  
4.3.1  Frontal analysis studies 
Frontal analysis was used to examine the overall interactions of tolazamide with 
normal or glycated HSA, as described in prior work in section 3.3.1 [10].  In this method, 
a drug solution with a known concentration was continuously applied onto a 
microcolumn containing one of these protein preparations.  During application of the 
drug solution, the amount of drug that eluted was monitored and formed a breakthrough 
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curve.  These curves reached stable plateaus within 2.5-4.0 min under the given 
conditions.  The precision for the moles of bound tolazamide that were measured during 
these experiments ranged from ± 0.1-5.5% (average, ± 1.8%). Each frontal analysis 
chromatogram for tolazamide showed a small initial plateau (i.e., at about 2.2-2.5 min) 
which represented the void volume and which was created by a slight difference in the 
background absorbance of the tolazamide solution when compared to the application 
buffer.  The frontal analysis results after the void volume and with normal HSA gave a 
set of two curves at the higher concentrations of applied tolazamide, indicating that 
multiple types of binding sites were present for this drug.  The glycated HSA samples 
exhibited only one overall breakthrough curve beyond the void volume, demonstrating 
that some changes in the binding of tolazamide had taken place in going from normal 
HSA to glycated HSA.  The overall breakthrough time for the combined curves in each 
plot, beyond the void volume, were used to determine the binding capacity for tolazamide 
to the immobilized HSA; this approach for data analysis made it possible to directly 
compare the results obtained at different concentrations of tolazamide with the same 
preparation of HSA or on different types of HSA microcolumns. The overall binding 
capacities that were measured at different applied concentrations of tolazamide were fit to 
various binding models to obtain the equilibrium constants and amounts of binding sites 
for these interactions [13]. Eq. 3-3 was used to examine the higher or lower affinity 
binding sites on HSA for tolazamide, as described in Section 3.3.1. The presence of any 
secondary binding and interactions the analyte or drug may have with the support was 
also considered.   
76 
 
The results of these fits are shown in Table 4-1.  These results were obtained 
using a best-fit value of 1.34 (± 0.01) × 103 M-1 for KaS (i.e., representing binding by 
tolazamide to the support) and a value of 8.3 (± 0.1) × 10-7 mol for mS (i.e., the moles of 
binding sites for tolazamide on the support in the absence of any HSA).  Based on the 
results shown in Table 4-1, the presence of HSA led to a decrease in secondary binding 
between tolazamide and the support.  For example, the data for the fit of the two-site 
drug/protein binding model in Table 4-1 indicated that about half (51%) of the original 
binding sites for tolazamide on the support were still available to tolazamide once normal 
or glycated HSA had been immobilized.  Use of a one-site drug/protein model similarly 
indicated that 58-60% of the original sites on the support were accessible for binding to 
tolazamide after protein immobilization. Figure 4-1 shows some typical frontal analysis 
data for tolazamide on a column containing HSA and when fit to Eqs. (3-3) and (3-4).  
For each type of HSA, it was found that the two-site drug/protein binding model, as 
described by Eq. (3-4), gave a much better fit to the data than a one-site drug/protein 
model based on Eq. (3-3).  These two types of fits had correlation coefficients ranging 
from 0.9998-0.9999 and 0.9829-0.9972 (n = 12), respectively, for all the types of HSA 
samples that were examined.  The fits to the two-site model based on Eq. (3-4) also gave 
more random variations of the data about the best-fit lines (see insets in Figure 4-1) and 
smaller values for the sums of the squares of the residuals.  In the latter case, values of 
0.1-2.0 × 10-18 were obtained for the two-site drug/protein binding model in Eq. (3-4) vs. 
values of 0.3-1.4 × 10-16 for the one-site drug/protein model in Eq. (3-3), with these 
differences being significant at the 95% confidence level. These results, and the general 
shape of the frontal analysis curves, indicated that the two-site drug/protein model was 
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better than the one-site model for describing interactions between tolazamide and normal 
HSA or glycated HSA.  This conclusion was consistent with the two-step frontal analysis 
curves that are shown in Figure 4-1(a) for normal HSA at moderate-to-high tolazamide 
concentrations.  This two-site model also agrees with previous findings for tolazamide 
and several other first-generation sulfonylureas with normal HSA or BSA [8,9], as well 
as for alternative first-generation sulfonylurea drugs with similar preparations of glycated 
HSA to those used in this study [4-9]. 
The association equilibrium constants and moles of binding sites that were 
obtained with the two-site drug/protein binding model are provided in Table 4-1 (Note: 
the results for the one-site model are also provided for reference).  The association 
equilibrium constants for the higher affinity sites that were found for tolazamide with 
normal HSA, gHSA1, and gHSA2 were 5.3 (± 0.6) × 104 M-1, 4.3 (± 0.5) × 104 M-1, and 
6.0 (± 0.2) × 104 M-1, respectively.  The precisions of these values varied from ± 3.3-11.6% 
(average, ± 8.8%).  This range of binding constants was similar to a value of 8.67 × 104 
M-1 that has been previously measured for the higher affinity sites of tolazamide at pH 7.4 
and 37ºC when using dynamic dialysis and a 1% solution of normal HSA [9].  In addition, 
these binding constants were consistent with binding strengths of 12-22 × 104 M-1, 8.4-12 
× 104 M-1, and 4.5-9.9 × 104 M-1 that have been reported for three other first-generation 
sulfonylurea drugs (i.e., acetohexamide, tolbutamide, and chlorpropamide, respectively) 
with normal HSA and glycated HSA [3-7, 9].   
The values obtained from the same fits for the binding strengths of the weak or 
non-specific sites (as represented by Ka2) are also listed in Table 4-1.  The value of this 
term for normal HSA, gHSA1, and gHSA2 was 0.49 (± 0.01) × 104 M-1, 0.85 (± 0.27) × 
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104 M-1, or 0.91 (± 0.01) × 104 M-1, respectively (i.e., binding constants that were 5.1- to 
10.8-fold lower than Ka1 for the higher affinity sites).  The precisions of these Ka2 values 
ranged from ± 1.1-32% (average, ± 11.6%).  These binding constants were similar to 
those for weak/non-specific sites that have been reported for three other first-generation 
sulfonylurea drugs with normal HSA and glycated HSA [3-7, 9].   
The amounts of binding sites that had a moderate-to-high affinity for tolazamide 
was found from the data in Table 4-1 to be 0.14-0.19 mol per mol HSA (average, 0.16) 
for the three types of normal or glycated HSA that were examined in this study.  These 
results were based on the content of HSA in each type of microcolumn (i.e., 41-45 nmol, 
as calculated by using the as calculated by using the measured amount of HSA on the 
support and the support’s known packing density) and the values for mL1 that are listed in 
Table 4-1, as obtained for the same preparations of HSA when using a two-site binding 
model.  These values suggested that only a portion of the immobilized HSA was active 
[5-8] and that only one or a few binding regions on HSA made up tolazamide’s higher 
affinity sites.  The number of lower affinity binding sites for tolazamide was found 
through the same approach to range from 3.9-19.6 (average, 14.0) mol per mol HSA. 
The data in Table 4-1 indicate that some changes occurred in the value of Ka1 at 
the moderate-to-high affinity sites for tolazamide when going from normal HSA to 
glycated HSA and using a two-site binding model.  For instance, there was a 19% 
decrease in the value of Ka1 for tolazamide when going from normal HSA to the gHSA1 
and a 13% increase between normal HSA and gHSA2.  Each of these differences was 
significant at 95% confidence level.  Both increased binding and decreased binding 
strength has been seen for other sulfonylurea drugs with HSA that had similar or identical 
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levels of glycation to that present in this study [3-7, 9]. These changes in affinity have 
been proposed to be due to glycation or related modifications that take place at or near 
Sudlow sites I and II [4-9,15-17].  In addition, an increase in Ka2 of 4.4- to 4.6-fold was 
seen for tolazamide in going from normal to glycated HSA.  This increase, along with the 
increase in the value of mL2 for these weak/non-specific sites, explains why two fronts 
were seen in the breakthrough curves for tolazamide with normal HSA (i.e., which had 
the largest difference between Ka1 vs. Ka2 and mL1 vs. mL2), while only one broad front 
was seen for the microcolumns that contained glycated HSA. 
 
4.3.2  Zonal competition studies 
4.3.2.1  Zonal elution studies with tolazamide at Sudlow site I 
            Zonal elution competition studies were used to investigate any site-specific 
changes in the binding of tolazamide with normal or glycated HSA and to identify the 
regions on this protein which made up the moderate-to-high sites that were represented 
by Ka1 in the frontal analysis studies.  In this method, a small amount of a site-specific 
probe (e.g., R-warfarin or L-tryptophan) was injected onto an HSA microcolumn in the 
presence of a mobile phase that contained a known and fixed concentration of tolazamide 
[18].  Figure 4-2 shows typical chromatograms for these competition experiments for 
normal HSA and gHSA1; similar behavior was seen for gHSA2.  In these studies, the 
probe eluted in under 1.5-2.0 min (for L-tryptophan) or under 7-8 min (for R-warfarin).  
The retention factor (k) for the probe was determined at each concentration of tolazamide 
in the mobile phase.  The precision of the retention factors for the injected probes in these 
studies ranged from ± 0.1-8.4% (average, ± 1.3%). 
80 
 
Previous studies have shown that direct interaction of a probe with a drug at a 
single site during a zonal elution experiment yields a linear relationship when plotted 
according to Eq. (3-5), as described in section 3.3.2. Examples of this type of plot are 
shown in Figure 4-3. Interactions of tolazamide at Sudlow site I were investigated by 
employing R-warfarin as the site-specific probe [10].  These experiments provided linear 
plots according to Eq. (3-5) for the columns that contained normal or glycated HSA.  The 
correlation coefficients of these plots spanned from 0.8962 to 0.9502 (n = 6-8).  These 
fits were consistent with a system in which tolazamide had direct interactions with R-
warfarin at Sudlow site I on normal and glycated HSA.  This result agreed with 
observations made in previous studies with other first-generation sulfonylurea drugs [5-8]. 
Table 4-2 shows the association equilibrium constants that were determined for 
tolazamide at Sudlow site I on each HSA microcolumn.  These values were 1.8 (± 0.3) × 
104 M-1, 1.4 (± 0.2) × 104 M-1, and 1.4 (± 0.3) × 104 M-1 for tolazamide on normal HSA, 
gHSA1 and gHSA2, respectively, and had precisions of ± 14-21% (average, ± 17%).  
These binding constants were within the range of 104-105 M-1 that was measured by 
frontal analysis for Ka1 at the moderate-to-high affinity sites of tolazamide on HSA, 
indicating that Sudlow site I was one of these regions.   There was a 22% decrease in the 
binding strength for tolazamide at Sudlow site I in going from normal HSA to both 
gHSA1 and gHSA2.  In each case, this decrease in local affinity was significant at the 95% 
confidence level.  These changes in binding strength are again probably related to 
glycation-related modifications that occur at or near Sudlow site I, as have been observed 
for residues K199, K276, and K281 on HSA [17]. 
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The results for tolazamide in the zonal elution studies were compared to those that 
have been measured by the same method with other first-generation sulfonylurea drugs 
(see Table 4-2).  In the case of acetohexamide, a non-significant decrease in binding  
strength of 3-10% has been noted at Sudlow site I with HSA that had similar or identical 
levels of glycation to that utilized in this study; however, lower levels of glycation gave a 
40% increase in the binding strength of acetohexamide at this same site [5,7].   Small-to-
moderate increases in binding strength have been noted for chlorpropamide and 
tolbutamide (i.e., increases of 10-21% and 18-20%, respectively) with samples of 
glycated HSA that were similar to those used in this report [4-7,9]. 
The difference in the relative direction and sizes of these changes in binding with 
glycated HSA and with the various sulfonylureas in Table 4-2 provides some clues as to 
the influence of their two side chains (i.e., R1 and R2) on these interactions.  As an 
example, tolazamide and tolbutamide both have a methyl group at R1, while tolazamide 
has a large azepane group at R2 and tolbutamide has a much smaller butyl group.  This 
comparison suggests that the 22% decrease in binding strength for the glycated HSA with 
tolazamide vs. the 18-20% increase with tolbutamide, and the 3.1- to 4.7-fold higher 
affinity seen for tolbutamide with both normal and glycated HSA, is due to a better fit of 
the smaller group at R2 on tolbutamide in Sudlow site I.  This observation is supported 
by the fact that chlorpropamide (i.e., which has only a propyl group at R2 and a chlorine 
at R1) has a similar binding strength and change in affinity to that seen with tolbutamide 
in going from normal HSA to glycated HSA. The binding strength and change in binding 
for acetohexamide at Sudlow site I are closest to the results for tolazamide.  This 
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similarity may be due to the relatively large cyclic rings that are present at R2 in both 
compounds. 
        
3.3.2.2 Zonal elution studies with tolazamide at Sudlow site II  
Similar zonal elution studies were used to examine the binding of tolazamide at 
Sudlow site II, for which L-tryptophan was used as a site-specific probe [10-11].  The 
average precision obtained for the retention factors in these studies was ± 1.5% (range, ± 
0.1-8.5%).  Plots of the resulting data were made according to Eq. (3-5), as illustrated in 
Figure 4-3(b).  These plots gave linear responses with correlation coefficients for all the 
tested protein samples that ranged from 0.8967 to 0.9653 (n =7-8).  This type of response 
indicated that tolazamide was binding at Sudlow site II in both normal and glycated HSA.  
Table 4-2 lists the site-selective binding constants that were measured for 
tolazamide at Sudlow site II for each type of HSA.  These values ranged from 1.9 to 3.0 × 
104 M-1 and had precisions of ± 14-23% (average, ± 18%).  These results were slightly 
larger than the binding constants measured for tolazamide at Sudlow site I and were again 
consistent with the values for Ka1 that were determined by frontal analysis for the 
moderate-to-high affinity sites of tolazamide on HSA.  These values given in Table 4-2 
for tolazamide at Sudlow site II were also the same order of magnitude but lower than 
binding constants that have been reported for acetohexamide and tolbutamide under 
comparable conditions with similar preparations of HSA [12-15].  There was a small, 
non-significant increase of 11% in the local affinity for tolazamide at Sudlow site II when 
comparing gHSA1 to normal HSA; however, there was also a 58% increase, which was 
significant at the 95% confidence level, in going from normal HSA to gHSA2.  These 
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changes were again thought to reflect modifications that were occurring at or near this 
site due to glycation, as have been observed at K378 and K439 [19-21].  
The results obtained for tolazamide at Sudlow site II were compared with those 
noted for other first-generation sulfonylurea drugs with similar samples of modified HSA 
[6-8].  In this case, chlorpropamide gave the closest behavior to that seen for tolazamide 
at Sudlow site II.  Chlorpropamide had local affinities that were similar to those seen for 
tolazamide and had an increase in affinity of up to 55% being seen in going from normal 
HSA to samples of glycated HSA [9].  These similarities indicated that Sudlow site II 
was mostly interacting with the R1 region of these compounds (i.e., a change from only a 
methyl group to a chlorine between tolazamide and chlorpropamide).  However, some 
interactions with R2 were probably present as well, as suggested by the differences in 
affinities at Sudlow site II that were seen between tolazamide and tolbutamide (i.e., both 
compounds having methyl groups at R1).  These conclusions agree with recent 
observations that have been made when comparing the interactions of chlorpropamide 
with those of acetohexamide and tolbutamide at Sudlow site II on normal or glycated 
HSA [9].  
 
4.4  Conclusion 
In this study, HPAC was used to investigate the binding of tolazamide to normal 
HSA and glycated HSA.  These results were then compared to those obtained in prior 
work with other first-generation sulfonylurea drugs.  Frontal analysis was first used to 
examine the overall interactions of tolazamide with the various preparations of HSA.  A 
two-site model yielded binding constants for tolazamide that included a set of moderate-
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to-high affinity regions (4.3-6.0 × 104 M-1) and a set of lower affinity regions (4.9-9.1 × 
103 M-1).  Both a slight decrease (19%) and small increase (13%) in binding strength at 
the higher affinity regions on HSA were seen for tolazamide at the two levels of 
glycation that were considered, which represented typical conditions seen in controlled or 
advanced diabetes.  Both these trends and binding model agreed with previous 
observations that have been made for other sulfonylurea drugs [4-7,9]. 
  Zonal elution studies were used to examine the interactions of tolazamide at 
specific sites on normal and glycated HSA.  This drug was found to bind to both Sudlow 
sites I and II, as has been reported for other first-generation sulfonylurea drugs [4-9].  A 
22% decrease in affinity was observed for tolazamide at Sudlow site I for the glycated 
samples of HSA when compared to normal HSA, while up to a 58% increase in affinity 
was observed at Sudlow site II.  These results were also consistent with prior 
observations made for other sulfonylurea drugs, which have typically been found to both 
Sudlow sites I and II and which can have increased or decreased affinities at these sites as 
a result of glycation [4-7,9]. 
The results for tolazamide at Sudlow sites I and II were compared in more detail 
to prior data obtained for related first-generation sulfonylurea drugs to learn more about 
the portions of these drugs that contributed to binding at each of these sites.  It was found 
that changes in the side group on the urea portion of these drugs (i.e., R2 in Table 4-2) 
were important in determining their affinities at Sudlow site I.   Changes at the side group 
on the phenysulfonyl region of these compounds (i.e., R1 in Table 4-2) were important in 
affecting binding at Sudlow site II; however, some contributions from R2 were also 
probably present at this site.     
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It was illustrated in this report how HPAC can be employed with affinity 
microcolumns to look at changes in both the overall binding and site-selective 
interactions that take place as a result of protein modification.  This approach was shown 
to be relatively fast, reproducible, and able to provide precise estimates of binding 
constants for such work.  It was these features, plus the ability to use a small amount of 
protein for many experiments, which made it possible to examine even relatively minor 
changes in the affinity of tolazamide for normal and glycated HSA.  These properties also 
made it possible to compare the binding behavior noted for tolazamide with that seen for 
related drugs and similar or equivalent preparations of normal or glycated HSA.  These 
results provided a better understanding of how HSA glycation can affect the transport and 
protein binding of sulfonylurea drugs in serum, as well as information that can be used in 
future studies aimed at personalized medicine based on these agents [4]. 
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Figure 4-1.  Fit of (a) one-site or (b) two-site drug/protein binding models to frontal 
analysis data for tolazamide with an immobilized sample of gHSA1, as 
obtained by using Eqs. (3-3) or (3-4), respectively, and including the use 
of a term to correct for secondary binding by tolazamide to the support.  
The insets show the corresponding residual plots.  The correlation 
coefficients for these fits were (a) 0.9965 and (b) 0.9999 (n = 12).   
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Figure 4-2.  Typical chromatograms obtained by zonal elution competition studies and 
in the presence of 0 or 20 µM tolazamide in the mobile phase for (a) the 
injection of L-tryptophan as a probe for Sudlow site II on a normal HSA 
microcolumn or (b) the injection of R-warfarin as a probe for Sudlow site I 
on a microcolumn containing gHSA1.  These chromatograms were 
acquired at a flow rate of 0.50 mL/min. 
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Figure 4-3.  Examples of zonal elution competition studies and plots made according 
to Eq. (3-5) when using tolazamide as a competing agent and (a) R-
warfarin as the injected probe on a column containing gHSA2 or (b) L-
tryptophan as the injected probe on a normal HSA column.  The 
correlation coefficients for these plots were (a) 0.9287 (n = 8) and (b) 
0.9653 (n = 8). 
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Table 4-1.  Best-fit parameters for the overall binding of tolazamide with normal HSA 
or glycated HSA based on one-site and two-site modelsa 
Type of HSA & 
binding model 
α Ka1  
(M-1 × 104) 
mL1  
(mol × 10-9) 
Ka2  
(M-1 × 104) 
mL2  
(mol × 10-7)     
 One-site model      
Normal HSA 0.58 (± 0.04) 3.4 (± 0.4) 48.4 (± 3.3) ------ ------ 
gHSA1 0.60 (± 0.02) 1.7 (± 0.1) 66.9 (± 2.2) ------ ------ 
gHSA2 0.60 (± 0.06) 3.9 (± 0.5) 40.4 (± 3.0) ------ ------ 
Two-site model      
Normal HSA 0.51 (± 0.01) 5.3 (± 0.6) 6.2 (± 0.3)  0.49 (± 0.01) 1.8 (± 0.1) 
gHSA1 0.51 (± 0.01) 4.3 (± 0.5) 7.6 (± 0.4)  0.85 (± 0.27) 8.0 (± 2.4) 
gHSA2 0.51 (± 0.01) 6.0 (± 0.2) 6.1 (± 0.2)  0.91 (± 0.01)   8.2 (± 1.1) 
 
aThese results were measured at pH 7.4 and 37 °C.  The ranges given in parentheses are ± 
1 S.D.  Eqs. (3-4) and (3-5) were used to obtain the parameters for the one-site and two-
site binding models of tolazamide with HSA by employing independent estimates for KaS 
and mLS of 1.34 (± 0.01) × 10
3 M-1 and 8.3 (± 0.1) × 10-7 mol. 
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Table 4-2.  Site-specific association equilibrium constants (Ka) determined by zonal 
elution for the binding of tolazamide and other first-generation 
sulfonylureas at Sudlow sites I and II of HSAa (see following page) 
 
aThese results were measured at pH 7.4 and 37 °C.  The ranges in parentheses are ± 1 S. 
D., as based on error propagation and the precisions of the best-fit slopes and intercepts 
obtained when using Eq. (3-4). 
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CHAPTER 5 
CHROMATOGRAPHIC CHARACTERIZATION OF INTERACTIONS BY 
FIRST- AND SECOND-SULFONYLUREA DRUGS WITH GLYOXAL-
MODIFIED ALBUMIN MICROCOLUMNS 
 
5.1 Introduction 
Sulfonylurea drugs like chlorpropamide, gliclazide, and tolazamide are known to 
have significant binding with human serum albumin (HSA), as described in Section 3.1 
[1-6]. HSA is known to be modified as a result of the presence of glucose and related 
products in blood [7-12].  For instance, glucose can react with free amino groups on HSA 
through a non-enzymatic process known as glycation to form a Schiff base that can then 
be converted into a stable fructosamine, as described in Section 3.1 [7].  Glyoxal, a type 
of α-oxoaldehyde, can be created from the oxidation of these glycated protein adducts, as 
well as through the auto-oxidation of glucose [13].  Glyoxal can then react with arginine 
or lysine residues on a protein such as HSA to form advanced glycation end-products 
(AGEs), as illustrated in Figure 5-1 [13-16].  Examples of these products are Nε-
carboxymethyl-lysine and glyoxal-derived hydroimidazolone isomer 1, as shown in Fig. 
5-2.  The formation of these AGEs in proteins is related to many of the complications that 
originate from high glucose levels, including atherosclerosis, retinopathy, nephropathy, 
and neuropathy [17-18].  This study will utilize high-performance affinity 
chromatography (HPAC) to examine the binding of chlorpropamide, gliclazide, and 
tolazamide to HSA that has been modified with various physiological levels of glyoxal.  
In this chapter, both the global and site-specific changes in the interactions of 
chlorpropamide, gliclazide, and tolazamide with glyoxal-modified HSA will be 
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investigated by using HPAC.  A comparison will be made between these results and prior 
measurements made with normal or glycated HSA [4-6] to see how alterations in the 
modifications of HSA or in the structure of these compounds affect these interactions.  
This information, in turn, should be useful in future work aimed at creating customized 
treatments based on these and other sulfonylurea drugs for personalized medicine [1]. 
5.2  Experimental 
5.2.1  Chemicals 
          The gliclazide (≥ 99.9% pure), R-warfarin (≥ 97%), L-tryptophan (≥ 98%), HSA 
(product A1887, from human serum, essentially fatty acid free, ≥ 96%), sodium dodecyl 
sulfate (≥ 99%), sodium tetraborate (≥ 99%), and glyoxal were from Sigma-Aldrich (St. 
Louis, MO, USA). The chlorpropamide (≥ 99%) and tolazamide (≥  99%) were 
purchased from Santa Cruz Biotechnology (Dallas, TX, USA).  The o-phthalaldehyde 
(OPA) (≥ 99%), 9,10-phenanthrenequinone (≥ 98%) were from TCI America (Portland, 
OR, USA).  The β-mercaptoethanol (≥ 98%) was from Alfa Aesar (Ward Hill, MA, USA). 
The Nucleosil Si-300 (pore size, 300 Å; particle size, 7 µm) was acquired from 
Macherey-Nagel (Duren, Germany).  The bicinchoninic acid (BCA) protein assay 
reagents were from Pierce (Rockford, IL, USA).  Water that had been purified by a Milli-
Q-Advantage A 10 system (EMD Millipore, Billerica, MA, USA) was used to make all 
the aqueous solutions and mobile phases that were utilized in this research.  These 
solutions were filtered by passing them through 0.20 µm GNWP nylon membranes from 
Fisher Scientific (Pittsburgh, PA, USA). 
 
5.2.2  Instrumentation 
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A Jasco (Tokyo, Japan) HPLC system was used in this report, as described in 
Section 3.2.2.   
 
5.2.3 Preparation of glyoxal-modified HSA 
HSA was modified with glyoxal by adapting previous conditions that have been 
used to prepare glycated HSA in vitro [19].  This modification was carried out under 
sterile conditions and using 1 mM sodium azide as a buffer additive to prevent bacterial 
growth [1-6].  All reaction mixtures were made in pH 7.4, 0.067 M potassium phosphate 
buffer that contained a typical physiological concentration of normal HSA (42 g/L) and 
either 130 nM or 210 nM of glyoxal (i.e., representing glyoxal levels in serum seen in 
healthy individuals or those with controlled diabetes, respectively) [20-21].  These 
conditions gave modified forms of HSA that are referred to in this paper as GoHSA1 and 
GoHSA2.  Each of these mixtures was incubated for about 4 weeks at 37 °C to allow the 
modification reaction to occur.  A desalting column was then used to remove the excess 
and unreacted glyoxal [36], followed by dialysis against water using Slide-A-Lyzer 
dialysis cassettes from Pierce.  The resulting samples of modified HSA were then 
lyophilized and stored at -80 °C. The level of modification for the HSA samples was 
determined by assays for free lysine or arginine residues, as described previously [22-23].  
In the assay for free arginine residues, a 1 mg/mL solution of the modified HSA was 
prepared in pH 7.4, 0.067 M potassium phosphate buffer, with a solution of normal HSA 
being prepared in the same manner as a reference.  A 1.0 mL portion of each protein 
solution was then combined with 3.0 mL of a 0.1 mg/mL solution of 9,10-
phenanthrenequinone in absolute ethanol, with 0.5 mL of 2 N sodium hydroxide then 
being added to this mixture and incubated in the dark for 3 h at 60ºC.  The 9,10-
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phenanthrenequinone solution was prepared immediately before each assay because it is 
light sensitive and unstable at room temperature [22].  After this incubation step, 0.5 mL 
of 1.2 N HCl was added to the solution in the dark and gently mixed by shaking.  The 
new combined solution was transferred to a cuvette and analyzed by making fluorescence 
measurements at excitation wavelength of 312 nm and an emission wavelength of 395 
nm [22]. Each sample measurement was carried out in quadruplicate.  
In the assay for free lysine residues [23], a 0.25 mM solution of normal HSA or 
modified HSA was prepared in pH 7.4, 0.067 M potassium phosphate buffer that also 
contained 2.5 mM sodium azide as an antibacterial reagent.  OPA (density, 1.13 g/mL) 
was dissolved in 1 mL of 95% ethanol at a concentration of 40 mg/mL; this solution was 
then mixed with 25 ml of 0.10 M sodium tetraborate in water and 2.5 mL of 20% (w/w) 
sodium dodecyl sulfate (SDS) in water. A 0.10 mL aliquot of β-mercaptoethanol was 
then added to this mixture. This reagent was stored in an amber bottle (i.e., to protect it 
from light) and with minimal air space, giving a working solution that was stable for 
several days [23].  A 50 µL portion of the 0.25 mM protein solution was then combined 
with 3.0 mL of the OPA reagent and allowed to react for 10 min in the dark at room 
temperature.  Fluorescence measurements were carried out at an excitation wavelength of 
340 nm and an emission wavelength of 455 nm [23] using normal HSA in water as the 
blank.  The lysine modification levels of the protein samples were determined indirectly 
by frustosamine assay results of glycated HSA samples based on a comparison of 
absorbance values between the AGE samples, glycated HSA and normal HSA.   
 
5.2.4 Column preparation 
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The affinity microcolumns were prepared in the same manner as described in 
Section 3.2.3. 
5.2.5  Chromatographic studies 
The solutions of gliclazide, L-tryptophan, R-warfarin and sodium nitrate were 
prepared in pH 7.4, 0.067 M phosphate buffer, which was also used as the mobile phase 
for the chromatographic studies (Note: this buffer was selected because it has been 
routinely used in prior studies to examine binding by other sulfonylurea drugs with HSA) 
[2-6,24].  This buffer was passed through a 0.2 µm filter and degassed for 10-20 min 
prior to its use.  The solutions of R-warfarin were used within two weeks of preparation, 
and the L-tryptophan solutions were used within 1-2 days, based on previous studies 
examining the stability of such solutions [24-26].  All the chromatographic experiments 
were performed at 0.50 mL/min and 37 °C.  The back pressure for the microcolumns 
under these conditions was 2.0 MPa (290 psi) or less.  As noted previously, no significant 
changes in the binding parameters that were measured in this work were seen when using 
other flow rates as long as sufficient time was applied for a local equilibrium to be 
established between the immobilized binding agent and the injected/applied drugs and 
probe compounds [1-5].     
The overall binding between sulfonylurea drugs and HSA were investigated by 
using zonal elution which was carried out by saturating an anti-HSA immunoaffinity 
microcolumn with 5.0 μM of controlled Go-modified HSA or diabetic Go-modified HSA. 
In this saturation process, any non-bound protein was removed by applying pH 7.4, 0.067 
M potassium phosphate buffer alone for 30.0 min at 0.10 mL/min. After equilibrating the 
column, 20.0 µL of each sulfonylurea drug was injected onto the retained HSA in the 
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antibody column using a concentration of 10.0 µM at a flow rate of 0.10 mL/min at 37oC, 
this was performed in triplicates.  Detection of each sulfonylurea drug was performed at 
its highest absorbance wavelength.  The detection wavelengths were as follows: 
tolazamide, gliclazide, 226 nm; tolbutamide, 228 nm; chlorpropamide, 231 nm; and 
warfarin, 308 nm.  All injections were made in triplicate. The microcolumn was 
regenerated after every 20 injection of these drugs samples by applying pH 2.5 0.10 M 
potassium phosphate buffer at 0.10 mL/min for 30 min. Control experiments were 
conducted by injecting the sulfonylurea drugs onto the anti-HSA column in the absence 
of HSA to measure possible interactions between the drugs and the immobilized 
antibodies.  The retention factor (k) of each drug was then tabulated by subtracting any 
possible extra-column interactions (i.e. antibody-drug and support-drug interactions) 
from HSA-drug interactions.  
The competition studies based on zonal elution were carried out by using R-
warfarin (i.e., a probe for Sudlow site I) and L-tryptophan (i.e., a probe for Sudlow site II) 
[24].  These studies were performed with eight different concentrations of gliclazide in 
the mobile phase, spanning from 0 to 20 μM.  The same solutions of gliclazide were used 
to make samples of the desired probe at a probe concentration of 5 µM (Note: the 
sulfonylurea drugs were added to minimize changes in the local concentration of this 
drug in the mobile phase, and the corresponding changes in the background response 
during sample injection, as has been used in prior studies with other sulfonylurea drugs) 
[2-6,24].  The injection volume for all samples was 20 µL.  The probe samples were 
injected onto each type of microcolumn while the probe was monitored at 308 nm for R-
warfarin or 280 nm for L-tryptophan.  A 20 µM solution of sodium nitrate, which was 
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used as a non-retained solute for the HSA and glycated HSA supports [24], was also 
injected onto each microcolumn, as well as onto the chromatographic system with no 
microcolumn present; this solute was monitored at 205 nm.  Each zonal elution 
experiment was carried out in quadruplicate, and the mean retention time of each peak 
was determined by using PeakFit 4.12.  
5.3  Results and discussion  
5.3.1  Characterization of Go-modified HSA and related supports 
 It is known that glyoxal can react with both lysine and arginine residues on 
proteins such as HSA [16].  These levels of modification were determined by using 
assays based on OPA and 9,10-phenanthrenequinone, respectively [22,23].  The 
modification levels of lysine in the samples of GoHSA1 and GoHSA2 were 2.6 (± 0.1) % 
and 4.2 (± 0.1) %. A 1.62-fold increase can be found in the relative levels change when 
comparing GoHSA2 with GoHSA1.   The levels of arginine modification for GoHSA1 
and GoHSA2 samples were 2.9 (± 0.4) % and 5.7 (± 0.3) %, respectively. A 1.97-fold 
increase relative change can be observed in the modification levels on GoHSA2 when 
compared to GoHSA1, which is consistent with levels of AGE modification on arginine 
that have been found on bovine serum albumin (BSA) under similar reaction conditions 
[27].  Examples of residues where the highest levels of these and other AGE 
modifications have been reported to occur on HSA include R521, R197, R117 and R428, 
as well as K525, K414, K51 and K439 [48]. The protein content of the supports that were 
prepared with these modified forms of HSA were also evaluated.  These supports were 
found to contain 89 (± 3), 55 (± 2) or 69 (± 4) mg HSA/g silica for the samples of NHSA, 
GoHSA1 and GoHSA2, respectively.  When these supports were placed into 1.0 cm × 2.1 
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mm i.d. microcolumns, they contained 0.86-1.08 mg (13-16 nmol) of GoHSA1 or 
GoHSA2.  Each of these columns was found to be stable when used over the course of 
about 300 injections and had typical backpressures of 1.5-2.0 MPa (220-290 psi) at a 
flow rate of 0.5 mL/min.   
5.3.2 Estimation of global binding for sulfonylureas with Go-modified HSA 
The global affinities of each sulfonylurea drug with GoHSA1 and GoHSA2 were 
performed by using zonal elution on samples of these proteins that were adsorbed to an 
anti-HSA microcolumn.   In this method, the retention factor (k) of each drug were 
obtained. These values were then used to calculate each sulfonylurea global affinity 
binding constant (nKa’) using Eq. (5-1), where mL is the moles of the ligand and Vm is the 
void volume of the column.   
                                                   𝑘  =
𝑛𝐾𝑎′ 𝑚𝐿
𝑉𝑚
                                                             (5-1) 
Based on Eq. (5-1), the values of nKa’ values that were found for gliclazide, 
chlorpropamide and tolazamide on normal HSA and the samples Go-modified HSA are 
summarized in Table 5-1. The results that were obtained for chlorpropamide at pH 7.4 
and 37℃ with NHSA, GoHSA1 and GoHSA2 were 5.9 (± 0.5) × 104 M-1, 7.5 (± 0.9) × 
104 M-1 and 7.8 (± 0.9) × 104 M-1, respectively.  The values for these same protein 
samples with gliclazide were 8.0 (± 1.2) × 104 M-1, 5.2 (± 0.8) × 104 M-1 and 6.4 (± 0.5) × 
104 M-1, while the values obtained with tolazamide were 2.8 (± 0.6) × 104 M-1, 3.4 (± 0.8) 
× 104 M-1 and 6.6 (± 0.8) × 104 M-1.  It can be observed that there is a 1.3-fold increase in 
global affinity for chlorpropamide when comparing GoHSA1 to normal HSA and 
GoHSA2 to normal HSA, respectively. A similar increase of 1.2-fold and 2.4-fold were 
found for tolazamide in going from normal HSA to GoHSA1 and GoHSA2, respectively. 
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However, a decrease of 0.7-fold and 0.8-fold was observed in global affinity for 
gliclazide when comparing GoHSA1 to normal HSA and GoHSA2 to normal HSA, 
respectively. The changes that observed for chlorpropamide and tolazamide were 
consistent with the results obtained from sulfonylurea drugs when comparing normal 
HSA to glycated HSA at various levels (i.e., 1.6-fold increase for chlorpropamide, 1.1-
fold increase for tolazamide) [2-6].  
5.3.3.  Site-selective binding of sulfonylureas with HSA 
5.3.3.1 General Approach 
Zonal elution is the most prevalent form of affinity chromatography that is used to 
examine the binding of solute-protein interactions at a specific region [22]. In this study, 
competition study based on zonal elution experiments provides a more detailed 
examination of how the binding of gliclazide changed at Sudlow sites I or II of HSA due 
to advanced glycation. These experiments were conducted by injecting a site-specific 
probe (e.g., R-warfarin or L-tryptophan) onto an HSA or glycated HSA microcolumn as a 
solution of gliclazide with a known and constant concentration was passed through the 
same microcolumn. Some typical chromatograms from these experiments as shown in 
Fig. 5-3.  The elution peaks of the probe compounds came out within 5 min or less under 
a flow rate of 0.50 mL/min.  Sodium nitrate, as a non-retained solute, was also injected to 
determine the void time. The retention time and retention factor (k) for each probe was 
then calculated as the concentration of gliclazide was varied. 
Eq. (5-2) can be used to describe this type of zonal elution system in which direct 
competition occurs at a single-site between an injected probe A and competing agent I. A  
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plot made of 1/k versus the molar drug concentration, [I], should follow the linear 
relationship that is given by Eq. (5-2) [49].   
1
 𝑘
=
𝐾𝑎I𝑉𝑀[I]
𝐾𝑎A𝑚𝐿
+
𝑉𝑀
𝐾𝑎A𝑚𝐿
                                                (5-2) 
The term KaA and KaI in Eq. (5-2) represent the association equilibrium constants for the 
probe and drug at their site of competition, while VM is the void volume, and mL is the 
apparent moles of the common binding sites the probe and drug have in the column.  If 
competition occurs between the drug and probe at a single common site, the KaI can be 
obtained from the ratio of the slope versus intercept for a plot made [28-30].  One 
advantage of this approach is it provides a value in the column for KaI that is independent 
of the moles of active protein or binding sites as well as any other interaction regions that 
probes does not interact with, as has been noted to be the case in prior work with the site-
selective probes that were employed in this study (i.e., R-warfarin and L-tryptophan) [28-
30]. 
5.3.3.2  Competition studies at Sudlow site I 
      Competition studies based on zonal elution experiments were first carried out for 
Sudlow site I by using R-warfarin as site-selective probe [28-30].  This site was of 
interest because it has been found to bind to other second-generation and third-generation 
sulfonylurea drugs (i.e., glipizide, glibenclamide and glimepiride) on both normal HSA 
and glycated HSA [2-4].  In this study, competition study between R-warfarin with each 
drug was carried out on columns containing glyoxal modified HSA at various levels. The 
data were analyzed by use of Eq. (5-2), as illustrated in Figure 5-4(a).  Linear plots were 
observed on both the GoHSA1 and GoHSA2 microcolumns, with correlation coefficients 
(n = 7-8) that spanned from 0.9947-0.9989 for gliclazide, 0.9866-0.9988 for 
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chlorpropamide, and 0.9554-0.9689 for tolazamide.  This behavior confirmed that the 
direct interactions between these drugs and R-warfarin at Sudlow site I on glyoxal-
modified HSA.  The average precision of the retention factors that were obtained in these 
measurements was ± 0.7% (range, ± 0.1-1.5%) for gliclazide, ± 0.3% (range, ± 0.1-0.5%) 
for chlorpropamide, and ± 0.5% (range, ± 0.1-1.3%) for tolazamide. Table 5-2 shows the 
association equilibrium constants for gliclazide that were measured at Sudlow site I on 
the GoHSA1 and GoHSA2 microcolumns. These values for gliclazide spanned from 2.0 
× 104 M-1 to 2.4 × 104 M-1 at pH 7.4 and 37ºC, with precisions of ± 4.2-5.0% (average, ± 
4.6%). The binding constants for chlorpropamide and tolazamide were in a general range 
of 5.1-5.4 × 104 M-1, 2.7-8.8 × 104 M-1, with precisions of ± 3.7-7.8% (average, ± 5.8%) 
and ± 14.8-15.9% (average, ± 15.4%), respectively, as shown in Table 5-2. Previous 
competition studies that were conducted in same manner gave an estimated binding 
constant of 1.9 (± 0.1) × 104 M-1 for gliclazide at Sudlow site I of normal HSA, which is 
also listed in Table 5-1 for comparison [4].  It was found that there was no significant 
change in the binding affinity for gliclazide when comparing GoHSA1 to normal HSA.  
However, a 1.26-fold increase in binding strength was found for gliclazide at Sudlow site 
I in going from normal HSA to GoHSA2, which was significant at the 95% confidence 
level.  Table 5-2 also shows the results for chlorpropamide and tolazamide at Sudlow site 
I on normal HSA column, as determined previously [12-13]. It was found that there is an 
increase in affinity for chlorpropamide of 1.38- or 1.31-fold when going from normal 
HSA to GoHSA1 or GoHSA2.  A similar increase of 1.50-fold was observed in the 
affinity for tolazamide when comparing GoHSA1 to normal HSA, while a 4.9-fold 
increase in the affinity was seen for tolazamide in going from normal HSA to GoHSA2. 
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All these differences were significant at the 95% confidence level.  Such changes in 
binding strength are believed to reflect the different amounts and types of modification 
that occur on HSA as its level of AGE formation is increased [1-7,31-34]. Look back to 
our previous work on glycated HSA, chlorpropamide had a similar tendency (i.e. 1.2-fold 
increase). However, the changes for tolazamide and gliclazide are reversed when 
comparing the results that obtained from glycated HSA (i.e. 0.8-fold decrease for 
tolazamide, 1.9-fold increase for gliclazide) [9-13].   Examples of specific modification 
sites for AGE formation that have been found to occur at or near Sudlow site I include 
K199, K281, K276 and R197 [31-34]. 
4.3.3.3. Competition studies at Sudlow site II  
 Competition studies were also used to examine the interactions of each drug at 
Sudlow site II by using L-tryptophan as a site-selective probe for this region [1-5, 30].  
Sudlow site II was of interest in this work because previous studies with gliclazide have 
suggested that this region has a relatively high affinity for this drug on both normal and 
glycated HSA [11].  This site is also known to bind other second-sulfonylurea drugs [1-3]. 
The results for each of drug that was examined in this study gave a linear plot for both 
GoHSA1 and GoHSA2 when the data were plotted according to Eq. (5-2).  An example 
of such a plot is provided in Figure 5-4(b).  The correlation coefficients (n = 7-8) for 
these plots ranged from 0.9606-0.9977 for gliclazide, 0.9837-0.9956 for chlorpropamide, 
and 0.9730-0.9879 for tolazamide. This behavior indicated that all of these drugs had 
direct interactions at Sudlow site II on both GoHSA1 and GoHSA2. The retention factors 
used to generate these plots had an average precision of ± 0.7% (range, ± 0.1-2.0%) for 
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gliclazide, ± 0.9% (range, ± 0.1-2.0%) for chlorpropamide, and ± 0.4% (range, ± 0.1-
0.7%) for tolazamide.  
 Table 5-1 shows the association equilibrium constants that were measured at 
Sudlow site II during these experiments for gliclazide with the samples of glyoxal-
modified HSA.  These values were in the range of 3.6-4.3 × 104 M-1 at pH 7.4 and 37ºC 
and had precisions of ± 2.3-13.8% (average, ± 8.1%).  The binding constant for gliclazide 
at Sudlow site II of normal HSA is also listed in Table 5-1 [11].  It was found through 
this comparison that modification with glyoxal gave a decrease in the affinity of 
gliclazide at Sudlow site II.  In this case, there was a 1.40-fold decrease in the affinity for 
gliclazide at Sudlow site II in going from normal HSA to GoHSA1 and a decrease of 
1.67-fold in going from normal HSA to GoHSA2, with all of these differences being 
significant at the 95% confidence level. 
Table 5-2 provides the measured binding constants at Sudlow site II for 
chlorpropamide and tolazamide on the Go-modified samples of HSA.  The values 
obtained for Ka were in a range of 4.4-6.2 × 10
4 M-1 for chlorpropamide and 2.8-3.2 × 104 
M-1 for tolazamide, with precisions of ± 4.8-9.1% (average, ± 7.0%) and 10.7-15.6 % 
(average, ± 13.2%), respectively. The results that have been obtained for the same drugs 
with normal HSA column are also listed in Table 5-2 [12-13].  When comparing these 
results, there was a 2.20-fold increase in the affinity for chlorpropamide at Sudlow site II 
for GoHSA1 vs. normal HSA and an increase of 3.10-fold in going from normal HSA to 
Go-HSA2. Tolazamide gave 1.47-fold and 1.68-fold increases when going from normal 
HSA to GoHSA1 or GoHSA2, respectively. All of these differences were significant at 
the 95% confidence level. These changes in binding were again probably a result of the 
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different amounts and types of modifications that occurred on these HSA samples [1-
5,31-34].  For instance, K439 and R428 are major sites for AGE formation that occur at 
Sudlow site II of HSA [31-34]. 
A closer examination of overall binding affinity for each sulfonylurea drug on 
each type of HSA was performed by combining the results at both Sudlow sites I and II.  
The combined association equilibrium constants for gliclazide, chlorpropamide and 
tolazamide with GoHSA1 were 6.3 (± 0.1) × 104 M-1, 9.8 (± 0.4) × 104 M-1 and 5.5 (± 0.5) 
× 104 M-1.  The corresponding values with GoHSA2 were 6.0 (± 0.5) × 104 M-1, 11.3 (± 
0.5) × 104 M-1 and 12.0 (± 1.5) × 104 M-1, respectively. When compared with normal 
HSA, there was a 1.7-fold or 2.0-fold increase in the combined association equilibrium 
constants for chlorpropamide and tolazamide on GoHSA1; however, there was a decrease 
of 0.8-fold for gliclazide with the same preparation of Go-modified HSA.  There were 
larger increases of 1.9-fold and 4.8-fold in these combined association equilibrium 
constants for chlorpropamide and tolazamide in going from normal HSA to GoHSA2, 
respectively; gliclazide again gave a 0.75-fold decrease for the Go-modified HSA. All of 
these changes were significant at the 95% confidence level. These changes gave similar 
trends with the results obtained from zonal elution studies based on the immunoaffinity 
microcolumn in Section 4.3.2 (i.e., 1.27-fold to 1.32-fold increase for chlorpropamide, 
1.2-fold to 2.4-fold increase for tolazamide and 0.7-fold to 0.8-fold decrease for 
gliclazide in going from normal HSA to GoHSA1 and GoHSA2, respectively). 
4.4.  Conclusion 
HPAC was used in this work to investigate the binding of first- and second-
generation sulfonylurea drugs, to HSA at levels of advanced glycation corresponding to 
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health adults or patients with diabetes.  Zonal elution-based competition studies were 
used to provide more site-specific information on the interactions between these drugs at 
Sudlow sites I and II of normal HSA or AGE-modified HSA.  The drugs in this study 
were found to bind to both Sudlow sites I and II, as has been noted for other sulfonylurea 
drugs [1-3].  Advanced glycation levels like those found in patients with diabetes gave a 
slight increase in the binding strength of gliclazide at Sudlow site I by up to 1.26-fold and 
an apparent decrease in binding strength at Sudlow site II of 1.67-fold when compared to 
the binding observed for normal HSA.  There was no significant difference in the binding 
of gliclazide at Sudlow site I but a 1.4-fold decrease at Sudlow site II in going from 
normal HSA to some of the Go-modified HSA. Similar results were obtained for 
chlorpropamide and tolazamide.  
Affinity microcolumns were used for examining drug-protein interactions in this 
report.  The small size of the affinity microcolumns made it possible to carry out detailed 
binding studies in a short time (minutes) and with systems up to affinities of 105 M-1 
under isocratic conditions.  The small amount of HSA in the microcolumns and the 
ability to reuse the columns for hundreds of binding experiments made it practical to use 
this approach with modified forms of HSA.  For instance, a single affinity microcolumn 
was used in this study for over 300 sample injections or application cycles, which was the 
equivalent of using less than 5 µg HSA per experiment.  The approach used in this report 
is not limited to AGEs but could be employed in binding studies with other modified 
proteins or even proteins that have been isolated from individual clinical samples [1].  
These features should result in further use of HPAC in bioanalysis and personalize 
medicine. 
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Figure 5-1. The processes of early stage glycation and advanced stage glycation. 
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Figure 5-2.  AGEs modification of (a) lysine and (b) arginine residue for the formation 
of glyoxal-modified HSA. 
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Figure 5-3.  Typical chromatograms obtained by zonal elution competition studies on a 
1.0 cm × 2.1 mm i.d. column containing diabetic Go-modified HSA and 
for the injection of R-warfarin in the presence of application of mobile 
phases that contained 20 or 0 µM gliclazide.  The flow rate was 0.50 
mL/min.  These studies were performed at 37°C and pH 7.4. 
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Figure 5-4.  Example of plots made according to Eq. (5-2) when using gliclazide as a 
competing agent in the mobile phase and (a) R-warfarin or (b) L-
tryptophan as the injected probe on a column containing controlled Go-
modified HSA.  The best-fit lines in (a) and (b) had correlation 
coefficients of 0.9947 and 0.9977, respectively.  The error bars represent ± 
1 S.D. 
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Table 5-1.  Overall association equilibrium constants (nKa’) for the interactions of 
several sulfonylurea drugs with normal or Go-modified HSA. 
Global affinity, nKa’ (M-1 × 104)a 
aTh
ese 
res
ults 
wer
e 
me
asured at 37 °C in the presence of pH 7.4, 0.067 M potassium phosphate buffer.  The 
values in parentheses represent a range of ± 1 S. D (n = 3). 
 
  
      Drug Normal HSA GoHSA1 GoHSA2 
Chlorpropamide 5.9 (± 0.5) [5] 7.5 (± 0.9) 7.8 (± 0.9) 
Gliclazide 8.0 (± 1.2) [4] 5.2 (± 0.8) 6.4 (± 0.5) 
Tolazamide 2.8 (± 0.6) [6] 3.4 (± 0.8) 6.6 (± 0.8) 
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Table 5-2.  Site-specific association equilibrium constants (Ka) for the interactions of 
chlorpropamide, gliclazide, and tolazamide at Sudlow site I and IIa 
Type of drug  
& HSA [Ref.] 
Sudlow site I 
Ka (M-1× 104) 
Change vs.  
Normal HAS 
Sudlow site II 
Ka (M-1× 104) 
Change vs. 
Normal HSA 
Chlorpropamide     
     Normal HSA [5] 3.9 (± 0.2)  ------ 2.0 (± 0.4)  ------ 
     GoHSA1 5.4 (± 0.2) ↑ 1.38-fold 4.4 (± 0.4) ↑ 2.20-fold 
     GoHSA2 5.1 (± 0.4) ↑ 1.31-fold 6.2 (± 0.3) ↑ 3.10-fold 
Gliclazide     
     Normal HSA [4] 1.9 (± 0.1) ------ 6.0 (± 0.5) ------ 
     GoHSA1 2.0 (± 0.1) ↑ 1.05-fold 
(N.S.)b 
4.3 (± 0.1) ↓ 1.40-fold 
     GoHSA2 2.4 (± 0.1) ↑ 1.26-fold 3.6 (± 0.5) ↓ 1.67-fold 
Tolazamide     
     Normal HSA [6] 1.8 (± 0.3) ------ 1.9 (± 0.3) ------ 
     GoHSA1 2.7 (± 0.4) ↑ 1.50-fold 2.8 (± 0.3) ↑ 1.47-fold 
     GoHSA2 8.8 (± 1.4)  ↑ 4.89-fold 3.2 (± 0.5)  ↑ 1.68-fold 
 
aThese results were measured at 37 °C in the presence of pH 7.4, 0.067 M potassium 
phosphate buffer.  The values in parentheses represent a range of ± 1 S. D., as based on 
error propagation and the precisions of the best-fit slopes and intercepts obtained when 
using Eq. (5-2) (n = 7-8). 
bThis value was not significantly different (N.S.) from that for normal HSA at the 95% 
confidence level. 
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CHAPTER 6 
 
CHROMATOGRAPHIC CHARACTERIZATION OF INTERACTIONS BY 
FIRST- AND SECOND-SULFONYLUREA DRUGS WITH METHYLGLYOXAL-
MODIFIED ALBUMIN MICROCOLUMNS 
 
6.1  Introduction 
The binding between first- and second-generation sulfonylurea drugs with HSA 
and glycated HSA have been examined, as described in  
Chapters 3-5 [1-4].  The high levels of glucose in blood during diabetes can lead to the 
non-enzymatic modification of HSA through a process known as glycation. In this 
process, the free amino groups on HSA initially react with the aldehyde group of glucose 
to form a reversible Schiff base.  This Schiff base can then convert to a stable Amadori 
product through rearrangement [5], as shown in Figure 5-1(a).  Additional reactions can 
also occur to form advanced glycation end-products (AGEs) through pathways such as 
hydration, oxidation and cross-linking steps [6-7]. Reactive aldehydes are produced due 
to the degradation of Amadori products, and these molecules can directly react with 
arginine and lysine residues on a protein; this results in the formation of AGEs [6-8], as 
illustrated in Fig. 5-1(b).     
Methylglyoxal (MGo) is a highly reactive aldehyde that is formed during these 
processes and which can combine with arginine and lysine residues on proteins to form 
AGEs [9]. One example is shown in Figure 6-1, in which MGo reacts with lysine and 
arginine to Nε-carboxyethyl-lysine (CEL) and methylglyoxal-derived hydroimidazolone 
isomer 1 (MG-H1), respectively. These types of AGEs have been found to be involved in 
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many of the complications that arise from hyperglycemia, including nephropathy, 
atherosclerosis, neuropathy and retinopathy [10, 11]. Recently, HSA has been applied in 
some research to examine how early stage glycation affects the structure of this protein 
and its interactions with drugs [1-4]. However, the effect of modifying HSA with MGo 
on these processes has not been examined in prior studies.  
The purpose of this study is to see how the binding of sulfonylurea drugs such as 
gliclazide, chlorpropamide and tolazamide change with HSA that has undergone 
modification with MGo.  These changes were examined by using high-performance 
affinity chromatography (HPAC), as described in Section 5.1. In this work, zonal elution 
will be employed with HPAC to examine the site-specific interactions of sulfonylureas 
with MGo-modified HSA. A comparison will then be made between the results and 
previous data obtained for the same drugs with normal, unmodified HSA. This 
comparison will make it possible to see how changes in the structure of proteins such as 
HSA can affect their binding processes [3]. The results should also provide a more 
complete picture on the effects of binding by sulfonylurea drugs to HSA during diabetes 
[3]. 
 
6.2.  Experimental 
6.2.1  Chemicals 
The chlorpropamide (≥ 96% pure), tolazamide (≥ 96% pure), gliclazide (≥ 96% 
pure), and R-warfarin (≥ 97% pure) were purchased from Santa Cruz Biotechnology 
(Dallas, TX, USA). L-Tryptophan (≥ 98%), HSA (lyophilized powder, essentially fatty 
acid free, ≥ 96% pure), methylglyoxal（~40 wt% in water), sodium azide (> 95%) and 
D-(+)-glucose (99.5%) were obtained from Sigma Aldrich (St. Louis, MO, USA). The 
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bicinchoninic acid (BCA) assay kit was purchased from Pierce (Rockford, IL, USA) and 
used to measure the protein content of each support. All buffers and drug solutions were 
prepared using purified water from a Milli-Q-Advantage A 10 system, and all the 
aqueous solutions were filtrated through 0.20 µm GNWP nylon membranes (both of 
which were purchased from EMD Millipore, Billerica, MA, USA). 
 
6.2.2.  Instrumentation 
The HPLC system utilized in this study was from Jasco (Tokyo, Japan), as 
described in Section 3.2.2.   
 
6.2.3.  Modification of HSA 
Two samples of MGo-modified HSA were prepared for this study: MGoHSA1 
and MGoHSA2.  These protein samples were prepared in vitro by using 40 nM or 120 
nM MGo and reaction conditions similar to those used in prior work to prepare glycated 
HSA [13].  The levels of MGo that were used to make these samples represented typical 
serum levels that are seen for this reactive aldehyde in healthy adults and patients with 
controlled-to-advanced diabetes [14].  Incubation of these solutions with a physiological 
level of HSA was carried out for about 4 weeks at pH 7.4 and 37 °C.  This was followed 
by use of a desalting column to remove any excess and unreacted MGo.  The MGo-
modified HSA samples were then lyophilized and stored at -80 °C.  
 
6.2.4. Column preparation 
The columns which contained MGo-modified HSA were prepared in the same 
manner as stated in a previous work with normal or glycated HSA, as described in section 
5.2.4 [4]. A control column containing no HSA was also made. The protein content of 
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each support was determined by using a BCA protein assay. In this assay, all the 
measurements were performed in triplicate; normal HSA was used as the standard, and 
the control support was used as the blank.  The protein contents were found to be 51 (± 1) 
and 65 (± 5) mg HSA/g silica for the MGoHSA1 and MGoHSA2 columns, respectively. 
The extent of modification for the arginine and lysine residues in the MGoHSA1 and 
MGoHSA2 samples were determined by means of fluorescent assays using 9,10-
phenanthrenequinone and o-phthalaldehyde (OPA) [4]. The protein supports were 
downward slurry packed into individual 1.0 cm × 2.1 mm i.d. stainless steel columns at a 
packing pressure of 3500 psi (24 MPa). In this work, potassium phosphate buffer (pH 7.4, 
0.067 M) was used as the packing buffer.  These microcolumns were found to contain 
0.79-1.01 mg of modified HSA, as calculated by using the known packing density of the 
support (i.e., 0.45 g silica/cm3) and the support’s measured protein content.  After 
packing, the columns and remaining supports (each kept the pH 7.4 phosphate buffer) 
were stored at 4 ℃ until use.  As has been reported in prior work [1-4], these 
microcolumns were stable during the course of this entire study (i.e., over 300 sample 
injections) without any significant changes in their binding properties or drug-protein 
interactions. 
6.2.5.  Chromatographic studies 
 
The chlorpropamide, tolazamide, gliclazide, L-tryptophan, R-warfarin and sodium 
nitrate solutions were prepared in pH 7.4, 0.067 M phosphate buffer, which acted as the 
mobile phase for the chromatographic studies (Note: this buffer resembles physiological 
conditions and has routinely been used to examine binding of other sulfonylurea drugs 
with HSA) [1-4, 14]. Before use, this buffer was passed through a 0.2 µm filter and 
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degassed for 10-20 min.  All solutions containing R-warfarin were used within two weeks 
of preparation, and the L-tryptophan solutions were prepared and used within 1-2 days 
[15-16]. All the chromatographic experiments were performed at 0.50 mL/min and 37 °C.  
The back pressure for the microcolumns under these conditions was 2.0 MPa (290 psi) or 
less. No significant changes in the binding properties were observed when compared with 
similar experiments performed at other flow rates, provided that sufficient time was 
allowed for an equilibrium to be established between the immobilized binding agent and 
the injected/applied drugs and probe compounds (R-warfarin and L-tryptophan) [1-4]. 
Zonal elution study was conducted to evaluate the overall affinity between 
sulfonylurea drugs and HSA by utilizing an immunoaffinity microcolumn. Anti-HSA 
antibodies were covalently immobilized onto silica for this purpose. This 
immunoextraction microcolumn was initially equilibrated with pH 7.4, 0.067 M 
potassium phosphate buffer at 0.10 mL/min and 37ºC for 60 min. Application of 
MGoHSA1 or MGoHSA2 to this column was done by using 5.0 µM solutions that were 
passed through the anti-HSA microcolumn at 0.10 mL/min until a breakthrough curve 
was obtained. A syringe pump was employed for protein application in this step. Any 
non-bound protein was then removed by applying the application buffer at the same flow 
rate for 30 min. For zonal elution studies, a small plug of the desired drug in the same pH 
7.4 buffer was injected. In this study, a 20.0 µL sample containing a 10.0 µM drug 
solution was injected onto chromatographic system; equivalent retention was seen for the 
injection of 2.5 µM drug samples, indicating that linear elution conditions were present. 
The detection wavelengths used in this work were 231 nm for chlorpropamide, and 226 
nm for gliclazide or tolazamide. All injections were made in a triplicate. The 
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microcolumn was regenerated by using pH 2.5, 0.10 M potassium phosphate buffer at 
0.10 mL/min for 30 min. Column regeneration was carried out after 20 drug sample 
injections in order to release the captured HSA. This process was repeated by passing a 
fresh solution of modified HSA to the immunoextraction column. Control experiments 
were conducted in the sample manner but with no MGoHSA1 or MGoHSA2 being 
passed through the immunoextraction microcolumn. These later experiments were used 
to measure any interactions that were present between the drugs and immobilized 
antibodies. The corrected retention factor (k) for each drug was found by subtracting the 
results obtained in the presence and absence of modified HSA on the immunoextraction 
microcolumn. 
A competition method based on zonal elution was performed by using R-warfarin 
(i.e., a probe for Sudlow site I) and L-tryptophan (a probe for Sudlow site II) [15].  Eight 
concentrations of each sulfonylurea drug, ranging from 0 to 20 μM, were applied in the 
mobile phase to the column. The same drug solutions were used to make 5 µM solutions 
of the probe compounds. (Note: This was done to minimize variations in the background 
signal due to difference in the local concentrations of the drug in the mobile phase versus 
the sample) [1-4, 15].  The sample injection volume was 20 µL. The probe samples were 
injected onto each microcolumn while monitoring their absorbance at 308 nm for R-
warfarin and 280 nm for L-tryptophan. A sample containing 20 µM of sodium nitrate was 
used as a non-retained solute, which was monitored at 205 nm [15]. Sodium nitrate was 
also injected onto the chromatographic system with no microcolumn present to obtain the 
system void time. All zonal elution experiments were carried out in quadruplicate, and 
the retention time of each peak was determined by using PeakFit 4.12. 
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6.3.  Results and discussion  
6.3.1.  Determination of AGEs levels of MGo-modified HSA 
 The measured levels of arginine modification for the MGoHSA1 and MGoHSA2 
samples were 5.6 (± 0.3) % and 13.1 (± 0.2) %, respectively. It is found that there is a 
2.33-fold increase in relative change of modification levels when comparing MGoHSA2 
with MGoHSA1, which was consistent with levels of modification for arginine that have 
been seen with BSA in prior studies [17-19]. The lysine modification levels for the 
MGoHSA1 and MGoHSA2 samples were 1.6 (± 0.1) % and 3.4 (± 0.1) %. A 2.11-fold 
increase can be observed in relative change of modification levels on MGoHSA2 when 
compared to MGoHSA1. Arginines R410, R114, R186 and R428 and lysines K525, 
K414, K12 and K233 have been reported to be the regions on HSA that undergo the 
highest levels of modification with agents such as MGo [20]. 
 As evaluated through a BCA protein assay, the supports contained 51 (± 1) and 65 
(± 1) mg protein/g silica for MGoHSA1 and MGoHSA2, respectively. When placed in 
microcolumns with dimensions of 1.0 cm × 2.1 mm i.d., about 0.80-1.02 mg (12-15 nmol) 
of these modified forms of HSA were present. These columns experienced backpressures 
of 1.5-2.0 MPa (220-290 psi) at a flow rate of 0.5 mL/min and were found to be stable 
over the course of 300 injections. 
 
6.3.2 Estimation of global binding for sulfonylureas with MGo-modified HSA 
 The global affinities of sulfonylurea drugs used in this study were measured for 
MGoHSA1 and MGoHSA2 by using zonal elution, as described in section 5.3.2. Table 6-
1 summarizes the nKa’ values that were obtained for gliclazide, chlorpropamide and 
tolazamide on the MGo-modified HSA samples and compares these results with those for 
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normal HSA from the literature. All these values were obtained at 37 ºC and using pH 7.4, 
0.067 potassium phosphate buffer as the mobile phase. In the case of chlorpropamide, the 
values obtained were 5.9 (± 0.5) × 104 M-1, 7.6 (± 0.5) × 104 M-1 and 10.3 (± 0.5) × 104 
M-1, for normal HSA, GoHSA1 and GoHSA2 respectively. The values obtained with 
gliclazide were 8.0 (± 1.2) × 104 M-1, 12.6 (± 0.8) × 104 M-1 and 8.4 (± 0.4) × 104 M-1 for 
these same protein samples, whereas tolazamide gave global affinity constants of 2.8 (± 
0.6) × 104 M-1, 6.4 (± 0.7) × 104 M-1 and 4.7 (± 0.5) × 104 M-1. About 1.3- to 1.8-fold 
increase in global affinity was obtained for chlorpropamide when comparing the values 
for MGoHSA1 and MGoHSA2 with that of normal HSA. In going from normal HSA to 
MGoHSA1, tolazamide showed a 2.3-fold increase in affinity, however this increase was 
around 1.7-fold for MGoHSA2. No significant increase was been observed for gliclazide 
on MGoHSA2 when compared to normal HSA. Gliclazide showed a similar trend to 
chlorpropamide and tolazamide, with an increase in global affinity of 1.6-fold between 
MGoHSA1 and normal HSA. Similar consistency was found for these sulfonylurea drugs 
when their changes in global affinities were compared to those seen previously for 
glycated HSA [1-4]. 
6.3.3  Site-selective binding of sulfonylureas with MGo-modified HSA 
6.3.3.1 Theory 
Zonal elution can also be used for the analysis of solute-ligand interactions at a 
specific region [19]. In this work, zonal competition elution was used which to provide 
detailed information about how the binding of the sulfonylurea drugs changed at the 
major binding regions on HSA (i.e., Sudlow sites I and II) due to modification with MGo, 
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as described in section 5.3.1. A typical chromatogram of zonal elution in this study, as 
shown in Figure 6.2. 
6.3.3.2 Interactions at Sudlow site I  
          R-Warfarin was used as a site-selective probe for Sudlow site I during the 
competition studies and zonal elution experiments [21-24].  This site was of interest 
because other second-generation sulfonylurea drugs (i.e., glipizide and glibenclamide) 
have been found to bind here on both normal HSA and glycated HSA [1-2].  In this study, 
R-warfarin was used as a probe with mobile phases containing gliclazide, chlorpropamide 
and tolazamide and using columns containing MGoHSA1 or MGoHSA2. The data were 
analyzed by using Eq. (5-2), as illustrated in Figure 6-3(a).  Linear relationships were 
observed for gliclazide on the MGoHSA1 and MGoHSA2 columns during these 
experiments, with correlation coefficients ranging from 0.9949 to 0.9952 (n =7-8). 
Similar linearities were found on these columns for chlorpropamide, with correlation 
coefficients of 0.9824 to 0.9927 (n =7-8), and for tolazamide, with correlation 
coefficients of 0.9035 to 0.9671 (n = 6-8). This behavior indicated that there was direct 
competition between these drugs and R-warfarin at Sudlow site I on the methylglyoxal-
modified HSA. The average precision of the retention factors obtained in these 
measurements was ± 2.6% (range, ± 0.6-6.1%) for gliclazide, ± 1.8% (range, ± 0.2-4.2%) 
for chlorpropamide and ± 3.0% (range, ± 0.1-7.2%) for tolazamide. The association 
equilibrium constants that were obtained in these studies at Sudlow site I are provided in 
Table 6-1. The equilibrium constants for gliclazide on the MGoHSA1 and MGoHSA2 
columns were 2.3 × 104 M-1 and 4.9 × 104 M-1 at pH 7.4 and 37 ºC, with precisions of ± 
4.3-6.1% (average, ± 5.2%).  Prior work that was conducted in same manner gave an 
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estimated binding constant of 1.9 × 104 M-1 for gliclazide at Sudlow site I of normal HSA, 
is also listed in Table 6-1 [1-4]. It was found that there was a 1.2-fold increase in the 
binding strength for gliclazide at Sudlow site I in going from normal HSA to MGoHSA1. 
A larger increase of about 2.6-fold occurred for gliclazide on the MGoHSA2 column vs. 
normal HSA. All of these differences were significant at the 95% confidence level. As 
shown in a previous study, the differences in binding is believed to reflect changes in the 
amounts and types of modification on HSA that were present [21-24].  K199, K281, 
K276 and R197 are prone to be specific modification sites due to glycation at or near 
Sudlow site I [25-28].    
The results for chlorpropamide and tolazamide are also shown in Table 6-2. The 
Ka values between chlorpropamide and MGoHSA1 or MGoHSA2 were 3.8× 10
4 M-1 and 
4.1× 104 M-1, with precisions of ± 4.9-7.9% (average, ± 8.4%).  There was no significant 
change in affinity for chlorpropamide at Sudlow site I when comparing both samples of 
MGo-modified HSA to normal HSA (i.e., 3.9× 104 M-1), as describe in section 3.3.2 [4].  
Similar patterns were seen for tolazamide, with no significant change in binding for 
MGoHSA1 but a decrease in binding strength of 0.83-fold when comparing MGoHSA2 
with normal HSA. 
  
6.3.3.3 Interactions at Sudlow site II  
L-Tryptophan was used as a site-selective probe for competition studies to 
examine the interactions by the sulfonylurea drugs at Sudlow site II of HSA [1-4]. Linear 
curves were obtained by plotting the data according to Eq. (5-2) from these sulfonylurea 
drugs with both samples of MGo-modified HSA. An example of such a plot is shown in 
Figure 6-3 (b).  The correlation coefficients of these plots for gliclazide ranged from 
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0.9848 to 0.9975 (n = 7-8), which indicated that gliclazide had direct interactions at 
Sudlow site II with both MGoHSA1 and MGoHSA2. The retention factors for the probe I 
this case had an average precision of ± 5.4% (range, ± 1.0-11.2%). Direct competition at 
Sudlow site II was also found to occur through these plots for the first-generation drugs 
chlorpropamide and tolazamide on the MGoHSA1 and MGoHSA2 columns. The 
correlation coefficients for chlorpropamide ranged from 0.9474 to 0.9597 (n = 7-8) and 
the retention factors had an average precision of ± 6.2% (range, ± 1.3-16.2%). For 
tolazamide, the correlation coefficients ranged from 0.9568 to 0.9798 (n = 7-8) and the 
retention factors had an average precision of ± 6.6% (range, ± 0.9-16.1%). Table 6-2 
includes the association equilibrium constants at Sudlow site II for gliclazide with the 
MGo-modified HSA samples.  The constants ranged from 10.4-14.8 × 104 M-1 at pH 7.4 
and 37ºC. The precision of these values was ± 4.8-8.8% (average, ± 6.8%).  The results 
for normal HSA, as based on prior work, is also listed in Table 6-2 for comparison [1-4]. 
A 1.2- to 2.6-fold increase was seen for gliclazide at Sudlow site II was observed when 
going from normal HSA to MGoHSA1 or MGoHSA, with all of these differences being 
significant at the 95% confidence level.  
Information for the affinity of chlorpropamide and tolazamide at Sudlow site II on 
both the MGo-modified HSA columns are also shown in Table 6-2. The values for 
chlorpropamide ranged from 2.0-5.3 × 104 M-1, with an average precision of ± 16% 
(range, 15-17%).  For tolazamide, the affinity ranged from 1.8-2.5 × 104 M-1 with an 
average precision of ± 11.5% (range, 11.1-12.0%).  There was no significant change in 
affinity for either of these drugs when going from normal HSA to MGoHSA1.  However, 
for MGoHSA2 there was an increase of 2.7-fold for chlorpropamide and an increase of 
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1.3-fold for tolazamide. These changes in binding were again probably due to the 
variations in the amount and types of modification on the HSA samples [3-4, 21-24].  For 
instance, K439 and R428 are known to be two major sites for AGE-based modifications 
that are at or near Sudlow site II of HSA [25-28]. By combining association equilibrium 
constants that were measured for Sudlow site I and II, it was possible to obtain a second 
estimate of the overall binding affinity for each drug with HSA. For gliclazide, 
chlorpropamide and tolazamide, these values were 17.1 (± 1.3) × 104 M-1, 5.8 (± 0.4) × 
104 M-1 and 3.7 (± 0.3) × 104 M-1 for MGoHSA1. The corresponding combined 
equilibrium constants for MGoHSA2 were 15.3 (± 0.6) × 104 M-1, 9.4 (± 0.9) × 104 M-1 
and 4.0 (± 0.5) × 104 M-1, respectively. These values were consistent with the estimated 
given in Table 6-1, indicating that Sudlow sites I and II were the major binding regions 
for these drugs with the MGo-modified forms of HSA. 
6.4  Conclusion 
 
This study examined the binding of several sulfonylurea drugs with HSA that had 
been modified with MGo at levels seen in healthy adults or in patients with diabetes. All 
of these drugs were found to bind to both Sudlow sites I and II, as has been noted for 
other sulfonylurea drugs with normal HSA [1-4]. Zonal elution-based competition studies 
were used to provide more site-specific information about the interactions between these 
drugs and MGo-modified HSA at Sudlow sites I and II. Significant changes were 
generally seen for these drugs with MGo-modified HSA that had been prepared under 
conditions to mimic those seen in controlled-to-advanced diabetes, with these changes 
ranging from a 0.83-fold decrease to a 2.7-fold increase in affinity.  The methods used in 
this study are not limited to MGo-modified HSA but could be employed in binding 
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studies with other types of modified proteins or even proteins isolated from clinical 
samples [29]. 
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Figure 6-1.  Examples of modifications of (a) lysine and (b) arginine residues that may    
occur during the formation of MGo-modified HSA.   
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Figure 6-2.  Typical chromatograms obtained by zonal elution competition studies on a 
1.0 cm × 2.1 mm i.d. column containing diabetic MGo-modified HSA and 
for the injection of R-warfarin in the presence of application of mobile 
phases that contained 20 or 0 µM gliclazide.  The flow rate was 0.50 
mL/min.  These studies were performed at 37°C and pH 7.4. 
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Figure 6-3.  Example of plots made according to Eq. (5-2) when using gliclazide as a 
competing agent in the mobile phase and (a) R-warfarin or (b) L-
tryptophan as the injected probe on a column containing controlled MGo-
modified HSA.  The best-fit lines in (a) and (b) had correlation 
coefficients of 0.9952 and 0.9948, respectively.  The error bars represent ± 
1 S.D. 
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Table 6-1.  Global affinity constants (nKa’) for the interactions of sulfonylurea drugs 
with normal or MGo-modified HSA. 
Type of HSA &  
global affinity, nKa’ (M-1 × 104)a 
      Drug Normal HSA MGoHSA1 MGoHSA2 
Chlorpropamide 5.9 (± 0.5) [32] 7.6 (± 0.5) 10.3 (± 0.5) 
Gliclazide 8.0 (± 1.2) [29, 
30] 
12.6 (± 0.8) 8.6 (± 0.4) 
Tolazamide 2.8 (± 0.6) [31] 6.4 (± 0.7) 4.7 (± 0.5) 
aThese results were measured at 37 °C in the presence of pH 7.4, 0.067 M potassium 
phosphate buffer.  The values in parentheses represent a range of ± 1 S. D (n = 3). 
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Table 6-2.  Site-specific association equilibrium constants (Ka) for the interactions of 
chlorpropamide, gliclazide, and tolazamide at Sudlow site I and IIa 
Type of drug  
& HSA [Ref.] 
Sudlow site I 
Ka (M-1× 104) 
Change vs.  
Normal HSA 
Sudlow site II 
Ka (M-1× 104) 
Change vs. 
Normal HSA 
Chlorpropamide     
     Normal HSA [32] 3.9 (± 0.2)  ------ 2.0 (± 0.4)  ----- 
     MGoHSA1 3.8 (± 0.3) N.S. 2.0 (± 0.3) aN.S. 
     MGoHSA2 4.1 (± 0.2) ↑ 1.05-fold aN.S. 5.3 (± 0.9) ↑ 2.7-fold 
Gliclazide     
     Normal HSA [29, 30] 1.9 (± 0.1) ------ 6.0 (± 0.5) ----- 
     MGoHSA1 2.3 (± 0.1) ↑ 1.2-fold 14.8 (± 1.3) ↑ 2.5-fold 
     MGoHSA2 4.9 (± 0.3) ↑ 2.6-fold 10.4 (± 0.5) ↑ 1.7-fold 
Tolazamide     
     Normal HSA [32] 1.8 (± 0.3) ------ 1.9 (± 0.3) ----- 
     MGoHSA1 1.9 (± 0.2) ↑ 1.05-fold aN.S. 1.8 (± 0.2) aN.S. 
     MGoHSA2 1.5 (± 0.4)  ↓ 0.83-fold 2.5 (± 0.3)  ↑ 1.3-fold 
aThese results were measured at 37 °C in the presence of pH 7.4, 0.067 M potassium 
phosphate buffer.  The values in parentheses represent a range of ± 1 S. D., as based on 
error propagation and the precisions of the best-fit slopes and intercepts obtained when 
using Eq. (5-2) (n = 7-8). 
bThis value was not significantly different (N.S.) from that for normal HSA at the 95% 
confidence level. 
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CHAPTER 7 
SUMMARY AND FUTURE WORK 
7.1  Summary 
 HPAC was used in this thesis to investigate the binding of various sulfonylurea 
drugs to normal HSA, glycated HSA and AGE-modified HSA. The results from frontal 
analysis experiments and using a two-site binding model indicated that most of 
sulfonylurea drugs that were examined had relatively strong binding with normal HSA 
and glycated HSA. Zonal elution studies were used to provide information on the 
interactions between sulfonylurea drugs at Sudlow sites I and II on normal HSA, glycated 
HSA and AGE-modified HSA.  These drugs were found to bind to both Sudlow site I and 
II, and it was also found that glycation or AGE modification could either increase or 
decrease the binding strength of these drugs to these sites.  This data should provide a 
better insight in determining how effective the dosage of a sulfonylurea drug may change 
as the glucose concentration in blood and protein glycation levels vary in diabetic 
patients. 
 The first chapter provided a general introduction to HPAC and use of HPAC for 
investigating the effects of interactions between drug and protein due to glycation.  The 
processes of protein glycation (i.e. early stage glycation and advanced stage glycation) 
was discussed. The change of structure and binding of HSA during glycation were also 
considered.  Frontal analysis and zonal elution, as common chromatographic approach, 
were next introduced and utilized to demonstrate how HPAC could be used as a tool to 
provide information about interactions between drug and protein.  
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Chapters 3-4 contained two studies which utilized HPAC to examine how 
glycation can affect the binding of two first-generation sulfonylurea drugs (i.e., 
chlorpropamide and tolazamide) to normal HSA and HSA with levels of glycation 
corresponding to controlled or advanced diabetes. Frontal analysis and zonal elution 
competition studies were applied and provided information about interactions between 
each drug with normal and glycated HSA.  It was found that a 0.8- to 1.6-fold change in 
affinity can be observed for the interactions of the sulfonylureas at each Suldow sites on 
glycated HSA when comparing with HSA.  These data should provide a better insight of 
glycation and provide useful information in altering the effective dose or free 
concentrations of these drugs and help in the use of these drugs for personalized medicine 
during the treatment of diabetes. 
Chapters 5-6 included several studies that involved the use of HPAC to examine 
the effects of advanced glycation end-product formation (i.e., glyoxal and methylglyoxal 
modification) on the binding of two first-generation sulfonylurea drugs (i.e., 
chlorpropamide and tolazamide) and a second-generation sulfonylurea drug (i.e., 
gliclazide) to HSA and samples of HSA with levels of advanced stage glycation (i.e., 
glyoxal and methylglyoxal modification) corresponding to healthy adults or patients with 
controlled diabetes. Immunoextraction zonal elution and zonal elution competition 
studies were applied and provided information about interactions between each drug with 
normal and glycated HSA. A 0.1- to 5.0-fold change in affinity was observed for the 
interactions of the sulfonylurea drugs at specific sites on AGE-modified HSA when 
compared to HSA. The results from immunoextraction zonal elution and competition 
studies indicated that modifications with methylglyoxal and glyoxal could significantly 
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affect the binding of these drugs to HSA. These results provided a better understanding of 
how HSA advanced stage glycation can affect the transport and protein binding of 
sulfonylurea drugs in serum, as well as information that can be used in future studies 
aimed at personalized medicine based on these agents. The approach used in this report 
could be employed in binding studies with other modified proteins or proteins that have 
been isolated from individual clinical samples [1]. 
In this study, frontal analysis and zonal elution competition method were both 
used to examine the interaction between sulfonylurea drugs and HSA with various levels 
of glycation. Frontal analysis could provide higher accuracy in the results for overall 
binding (i.e. the correlation coefficient value can reach to 0.9995). However, this 
chromatographic method required longer experimental times and larger amounts of 
targets. Zonal elution competition was of interest due to its faster analysis time and 
ability to work with smaller amounts of an analyte. The zonal elution method could also 
provide more binding information on the specific location of protein binding sites. Thus, 
zonal elution could be used to help us understand more about how glycation affects each 
major binding site of HSA in this research. 
7.2  Future work  
            The work in this thesis described the development and employment of HPAC and 
microcolumns for examining binding of various sulfonylurea drugs with proteins. The 
use of HPAC is not limited to determine the binding of chlorpropamide, tolazamide and 
gliclazide but could be used with other second-generation or third-generation 
sulfonylurea drugs (i.e. glipizide, glibenclamide and glimepiride) with glyoxal-modified 
HSA and methylglyoxal-modified HSA. The binding of other anti-diabetic drugs (i.e., 
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nateglinide, repaglinide, rosiglitazone and pioglitazone) to AGE-modified forms of HSA 
could also be examined by using HPAC and affinity microcolumns. Another approach 
may include the development of new immobilization methods to immobilize drug 
analogs and use these instead of proteins in HPAC microcolumns for binding studies. 
Through this approach, drugs with mild to strong binding affinities could be tested in 
their ability to extract transport proteins from serum. The immobilized drugs could also 
be tested to see if they ae capable of separating different types of modified proteins. This 
approach could then be used to identify and separate modified proteins that are present in 
clinical samples, which might then be used with mass spectrometry to identify key 
changes in structure that may underlie the observed changes in binding strength. 
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